CONDITIONALLY ACTIVE PROTEINS WITH pH SELECTIVITY

JP2024073516A5Active Publication Date: 2024-11-11BIOATLA LLC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024036509
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2018-08-21
Filing Date
2024-03-11
Publication Date
2024-11-11
Estimated Expiration
2039-08-20

AI Technical Summary

Technical Problem

Existing technologies struggle to produce polypeptides that are inactive under normal conditions but active under abnormal conditions, such as in tumor microenvironments, with improved activity and selectivity, and have increased half-lives to minimize side effects on normal tissues.

Method used

Introduce mutations in parent polypeptides to lower their isoelectric point (pI) and evolve conditionally active polypeptides with increased activity under abnormal conditions, such as pH changes, by substituting, deleting, or inserting amino acids with lower pI, and screen for variants with enhanced activity ratios under abnormal vs. normal conditions.

Benefits of technology

The method produces polypeptides with significantly higher activity under abnormal conditions, increased half-life, and reduced side effects on normal tissues, enabling targeted therapeutic applications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000056_0000
    Figure 00000056_0000
Patent Text Reader

Abstract

To provide a method of producing a conditionally active polypeptide from a parent polypeptide.SOLUTION: The method comprises steps of: (i) evolving the parent polypeptide by introducing mutations into the parent polypeptide to produce mutant polypeptides that have a pI equal to or lower than a pI of the parent polypeptide; (ii) subjecting the mutant polypeptides to a first assay under a normal physiological condition to measure the activity of the mutant polypeptides under the normal physiological condition, and to a second assay under an aberrant condition to measure the activity of the mutant polypeptides under the aberrant condition, where the normal physiological condition and the aberrant condition are the same condition but have different values; and (iii) selecting the conditionally active polypeptide from the mutant polypeptides exhibiting increased activity in the second assay compared to the same activity in the first assay. Conditionally active polypeptides and uses are also provided.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present disclosure relates to the field of providing polypeptides with conditional activity. In particular, the present disclosure relates to conditionally active polypeptides having pH-dependent activity and methods of making conditionally active polypeptides from parent polypeptides. [Background technology]

[0002] There is a large body of literature describing how to evolve proteins, particularly enzymes or antibodies, for various properties so that they are active or stable under various conditions. For example, enzymes have been evolved to be stable at high temperatures. In situations where enzyme activity improves at high temperatures, a substantial part of the improvement can be attributed to higher kinetic activity, which is generally explained by the Q10 rule (estimated to double metabolic turnover for every 10° C. increase for enzymes).

[0003] In addition, there are naturally occurring mutations that destabilize a protein under its normal operating conditions, thus reducing protein activity under normal operating conditions, for example, there are known temperature mutants that are active at lower temperatures, but typically at lower levels compared to the wild-type protein from which they are derived.

[0004] To evolve a parent polypeptide that is inactive or virtually inactive (less than 50%, 30%, or 10% activity and especially 1% activity) under its normal operating conditions but maintains comparable or better activity under abnormal conditions, it may be necessary for destabilizing mutations to coexist with activity-increasing mutations that do not counteract their destabilizing effect. It is expected that destabilizing mutations will reduce the activity of a polypeptide beyond the effect predicted by standard rules such as Q10, thus creating a conditionally active polypeptide, for example, by allowing the evolution of a polypeptide that is less active or inactive under its normal operating conditions but functions efficiently under abnormal conditions.

[0005] It is desirable to generate conditionally active polypeptides, e.g., polypeptides that are less active or effectively inactive under some conditions and active under other conditions. It is also desirable to generate polypeptides that are activated or inactivated in certain environments or over time. In addition to temperature, other conditions under which a polypeptide can be evolved or improved for conditional activity include pH, osmolality, oxidative stress, electrolyte concentration, etc. In addition to the activity of a polypeptide, it is often desirable to improve other properties during evolution, including chemical resistance and resistance to proteolysis.

[0006] Furthermore, the isoelectric point (pI) of the polypeptide is 1 / 2 It has been observed that the half-life of an antibody is inversely correlated with the half-life of the protein. See Momany et al., "Relationship between in vivo degradative rates and isoelectric points of proteins," PNAS, vol., 73, pp. 3093-3097, 1976. This is especially true for antibodies, since their half-life in plasma is positively correlated with their isoelectric point. In particular, antibodies with high pI values ​​not only have faster systemic clearance but also lower bioavailability compared to antibodies with low pI values. A 1-2 unit decrease in the pI of an antibody has been shown to correlate with a decrease in plasma clearance (i.e., a longer half-life). See Ryman, CPT Pharmacometrics Syst.Pharmacol., vol.6, pp. 576-588, 2017.

[0007] Strategies for altering the pI of polypeptides have been described. For example, US Patent No. 9,908,932 discloses a method for shifting the isoelectric point profile of a recombinant protein having seven protein subpopulations with pIs between about 5.45 and about 6.55. The method includes the steps of (a) culturing mammalian cells containing a nucleic acid encoding the recombinant protein in a production bioreactor for a first period of time under conditions sufficient to produce a product; and (b) incubating the product for a second period of time consisting of at least 6 hours under conditions sufficient to shift the isoelectric point profile of the product to a more acidic profile. The isoelectric point shifted product exhibits an increase in the amount of the fourth and fifth most acidic protein subpopulations of the seven protein subpopulations, and a decrease in the amount of the first and second most basic protein subpopulations of the seven protein subpopulations.

[0008] No. 9,605,061 discloses a method for modifying the pI of an antibody by introducing at least six amino acid mutations, including substitutions with non-native amino acids in a constant domain selected from one or both of the heavy and light chain constant domains, where the substituted amino acids have a lower pI than the native amino acids, such that the pI of the mutant antibody is reduced by at least 0.5 log relative to the pI of the parent antibody.

[0009] US2009 / 0324589 discloses a method for increasing the half-life of an IgG antibody in the blood by controlling the surface charge of the antibody through modification of surface-exposed residues of the antibody, including residues in the variable region. The method includes the steps of (a) modifying a nucleic acid encoding a parent polypeptide comprising an FcRn-binding domain to change the charge of at least one amino acid residue exposed on the surface of the parent polypeptide; (b) culturing a host cell to express the modified nucleic acid to express a variant polypeptide; and (c) recovering the expressed variant polypeptide comprising an FcRn-binding domain from the host cell culture.

[0010] There remains a need for conditionally active polypeptides with higher activity and / or selectivity under certain circumstances and / or conditions, preferably with increased half-life in plasma. Conditionally active polypeptides with increased half-life also act preferentially where abnormal conditions exist, such as tumor microenvironment, but also provide extended action or overall activity due to their increased half-life. Furthermore, these conditionally active polypeptides may cause fewer adverse side effects on normal tissues / organs where normal physiological conditions exist. The potential for reduced side effects allows for longer treatment or higher dose treatment, leading to higher efficacy of the conditionally active polypeptides.

[0011] WO 2010 / 104821 and WO 2011 / 009058 disclose methods for evolving and screening for conditionally active proteins. Summary of the Invention [Problem to be solved by the invention]

[0012] In one embodiment, the disclosure relates to a method for producing a conditionally active polypeptide from a parent polypeptide, comprising: (i) evolving a conditionally active polypeptide from a parent polypeptide by introducing one or more mutations into the parent polypeptide to produce one or more mutant polypeptides having a pI equal to or lower than the pI of the parent polypeptide; (ii) subjecting the one or more mutant polypeptides to a first assay under normal physiological conditions that measures an activity of the one or more mutant polypeptides under normal physiological conditions, and a second assay under abnormal conditions that measures an activity of the one or more mutant polypeptides under abnormal conditions, wherein the normal physiological conditions and the abnormal conditions are under the same conditions but have different values; and (iii) selecting from the one or more mutant polypeptides that show increased activity in the second assay compared to the same activity in the first assay.

[0013] In the foregoing embodiments, the conditionally active polypeptide may have a lower pI than the pI of the parent polypeptide.

[0014] In any one of the foregoing embodiments, the conditionally active polypeptide can have a pI below 7.4, or a pI below 7.3, or a pI below 7.2, or a pI below 7.1, or a pI below 7.0.

[0015] In any one of the preceding embodiments, the one or more mutations may include at least one amino acid substitution of an amino acid residue in the parent polypeptide for an amino acid residue in the parent polypeptide that has a higher pI than the pI of the amino acid substituted in the parent polypeptide.

[0016] In any one of the preceding embodiments, the one or more mutations may include 2, 3, 4, 5, 6, 7, 8, 9, or 10 of said substitutions.

[0017] In any one of the preceding embodiments, the one or more mutations may comprise at least one insertion of an amino acid residue having a lower pI than the pI of the parent polypeptide.

[0018] In any one of the preceding embodiments, the one or more mutations may include two, three, four, or five of said insertions.

[0019] In any one of the preceding embodiments, the one or more mutations may comprise a deletion of at least one amino acid residue having a pI higher than the pI of the parent polypeptide.

[0020] In any one of the preceding embodiments, the one or more mutations may include two, three, four, or five of said deletions.

[0021] In any one of the preceding embodiments, the one or more mutations may be located at positions exposed on the surface of the variant polypeptide.

[0022] In any one of the preceding embodiments, the evolving step may comprise the introduction of one or more additional mutations into the variant polypeptide.

[0023] Any one of the foregoing embodiments may further comprise the step of confirming that at least 50%, or at least 60%, or at least 70%, or at least 80%, or at least 90%, or at least 95%, or at least 98% of the variant polypeptides have a pI that is the same as or lower than the pI of the parent polypeptide.

[0024] The above embodiment may further comprise the step of discarding variant polypeptides having a pI greater than the pI of the parent polypeptide prior to step (ii).

[0025] Any one of the preceding embodiments can further comprise the step of measuring the pI of the conditionally active polypeptide.

[0026] In any one of the foregoing embodiments, the pI of the conditionally active polypeptide may be at least 0.1, at least 0.2, at least 0.3, at least 0.4, at least 0.5, at least 0.6, at least 0.8, at least 1.0, at least 1.2, at least 1.4, at least 1.5, at least 1.7, at least 2.0, at least 2.5, at least 3.0, at least 3.5, at least 4.0, or at least 5.0 units lower than the pI of the parent polypeptide.

[0027] In any one of the preceding embodiments, the parent polypeptide may be selected from an antibody, an enzyme, a hormone, a growth factor, a cytokine, a regulatory protein, a functional peptide, a biosimilar, an immunomodulatory drug, a receptor, and a ligand.

[0028] In any one of the preceding embodiments, the parent polypeptide may be an antibody selected from a full length antibody, a single chain antibody, an antibody fragment, a heavy chain, a light chain, a Fab, and an Fc domain.

[0029] In any one of the foregoing embodiments, the parent polypeptide may be a therapeutic antibody or an antibody candidate being developed for therapeutic use.

[0030] In any one of the preceding embodiments, the parent polypeptide may be an IgG antibody.

[0031] In any one of the preceding embodiments, the one or more mutations may be in the variable region of an IgG antibody.

[0032] In any one of the preceding embodiments, the one or more mutations may be in the constant region of an IgG antibody.

[0033] In any one of the preceding embodiments, the one or more mutations may be in one or more complementarity determining regions of the IgG antibody.

[0034] In any one of the preceding embodiments, the conditions may be selected from pH, temperature, osmolality, osmolality, oxidative stress, and electrolyte concentration.

[0035] In any one of the preceding embodiments, the condition may be pH.

[0036] In the foregoing embodiment, the pH of the first assay may be greater than 7.2 to less than 7.6, and the pH of the second assay may be less than 7.2 or greater than 7.6.

[0037] In any one of the foregoing embodiments, the ratio of the activity of the conditionally active polypeptide in the second assay to the same activity in the first assay may be at least 1.3, 1.5, or at least 1.7, or at least 2.0, or at least 3.0, or at least 4.0, or at least 6.0, or at least 8.0, or at least 10.0, or at least 20.0, or at least 40.0, or at least 60.0, or at least 100.0.

[0038] In any one of the preceding embodiments, both the first assay and the second assay may be performed in the presence of molecules or ions with a molecular weight of less than 900 a.mu, less than 500 a.mu, less than 200 a.mu, or less than 100 a.mu.

[0039] In the foregoing embodiments, the molecule or ion may be selected from histidine, histamine, hydrogenated adenosine diphosphate, hydrogenated adenosine triphosphate, citrate, bicarbonate, acetate, lactate, disulfide, hydrogen sulfide, ammonium, dihydrogen phosphate, and any combination thereof.

[0040] In the foregoing embodiments, the molecule or ion may be bicarbonate ion having a concentration in the range of about 3 mM to about 200 mM, about 5 mM to about 150 mM, about 5 mM to about 100 mM, about 10 mM to about 100 mM, about 20 mM to about 100 mM, about 25 mM to about 100 mM, about 30 mM to about 100 mM, about 35 mM to about 100 mM, about 40 mM to about 100 mM, or about 50 mM to about 100 mM.

[0041] In the foregoing embodiments, the molecule or ion may be disulfide ion having a concentration in the range of 1 mM to 100 mM, 2 nM to 500 nM, 3 nM to 200 nM, 5 nM to 100 nM.

[0042] In any one of the preceding embodiments, the molecule or ion may be selected from sodium bicarbonate, potassium bicarbonate, sodium disulfide, or potassium disulfide.

[0043] In any one of the foregoing embodiments, the physiological conditions may be normal physiological pH, and the abnormal conditions are an abnormal pH that is different from normal physiological pH, and the molecule or ion has a pKa between the normal physiological pH and the abnormal pH.

[0044] In the foregoing embodiments, the pKa of the molecule or ion may be up to 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.8, or 1.0, 2.0 units away from the abnormal pH.

[0045] In a second aspect, the disclosure relates to a conditionally active polypeptide derived from a parent polypeptide having a pI, said conditionally active polypeptide (a) having a pI that is the same or lower than the pI of the parent polypeptide, and (b) having a ratio of activity in a second assay under abnormal conditions to the same activity in a first assay under normal physiological conditions of at least 1.3, wherein the activity of the conditionally active polypeptide is measured in the presence of at least one molecule or ion having a molecular weight of less than 900 a.mu.

[0046] In a second embodiment, the molecular weight may be less than 500 a.mu, less than 200 a.mu, or less than 100 a.mu.

[0047] In any one of the foregoing embodiments, the ratio of activity in a second assay under abnormal conditions to the same activity in a first assay under normal physiological conditions may be at least 1.5, at least 1.7, or at least 2.0, or at least 3.0, or at least 4.0, or at least 6.0, or at least 8.0, or at least 10.0, or at least 20.0, or at least 40.0, or at least 60.0, or at least 100.0.

[0048] In any one of the foregoing embodiments, the pI of the conditionally active polypeptide can be at least 0.1, at least 0.2, at least 0.3, at least 0.4, at least 0.5, at least 0.6, at least 0.8, at least 1.0, at least 1.2, at least 1.4, at least 1.5, at least 1.7, at least 2.0, at least 2.5, at least 3.0, at least 3.5, at least 4.0, or at least 5.0 units lower than the pI of the parent polypeptide.

[0049] In any one of the preceding embodiments, the conditionally active polypeptide may be selected from an antibody, an enzyme, a hormone, a growth factor, a cytokine, a regulatory protein, a functional peptide, a biosimilar, an immunomodulatory drug, a receptor, and a ligand.

[0050] In any one of the preceding embodiments, the conditionally active polypeptide may be an antibody selected from a full length antibody, a single chain antibody, an antibody fragment, a heavy chain, a light chain, a Fab, and an Fc domain.

[0051] In the foregoing embodiments, the antibody may be an IgG antibody.

[0052] In any one of the preceding embodiments, the conditions may be selected from pH, temperature, osmolality, osmolality, oxidative stress, and electrolyte concentration.

[0053] In any one of the foregoing embodiments, normal physiological conditions may be a pH ranging from greater than 7.2 to less than 7.6, and abnormal conditions are a pH ranging from 5.5 to less than 7.2.

[0054] In the foregoing embodiments, the molecule or ion can have a pKa between normal physiological pH and abnormal pH.

[0055] In the foregoing embodiments, the pKa of the molecule or ion may be up to 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.8, or 1.0, 2.0 units away from the abnormal pH.

[0056] In any one of the preceding embodiments, the molecule or ion may be selected from histidine, histamine, hydrogenated adenosine diphosphate, hydrogenated adenosine triphosphate, citrate, bicarbonate, acetate, lactate, disulfide, hydrogen sulfide, ammonium, dihydrogen phosphate, and any combination thereof.

[0057] In any one of the foregoing embodiments, the molecule or ion may be bicarbonate ion having a concentration in the range of about 3 mM to about 200 mM, about 5 mM to about 150 mM, about 5 mM to about 100 mM, about 10 mM to about 100 mM, about 20 mM to about 100 mM, about 25 mM to about 100 mM, about 30 mM to about 100 mM, about 35 mM to about 100 mM, about 40 mM to about 100 mM, or about 50 mM to about 100 mM.

[0058] In any one of the preceding embodiments, the molecule or ion may be disulfide ion having a concentration in the range of 1 mM to 100 mM, 2 nM to 500 nM, 3 nM to 200 nM, 5 nM to 100 nM.

[0059] In any one of the previous embodiments, the molecule or ion may be selected from sodium bicarbonate, potassium bicarbonate, sodium disulfide, or potassium disulfide.

[0060] In yet another aspect, the disclosure relates to a pharmaceutical composition comprising an effective amount of a conditionally active polypeptide and a pharma- ceutically acceptable carrier.

[0061] In yet another aspect, the disclosure relates to the use of the conditionally active polypeptide for the treatment of a solid tumor, an inflamed joint, or a brain disease or disorder.

[0062] In yet another aspect, the disclosure relates to a method for treating a solid tumor, an inflamed joint, or a brain disease or disorder comprising administering to a patient in need of said treatment a conditionally active polypeptide. [Brief description of the drawings]

[0063] [Figure 1] Figure 1 shows the formation of salt bridges in deoxyhemoglobin, where three amino acid residues form two salt bridges, and these salt bridges stabilize the T quaternary structure of deoxyhemoglobin, leading to a reduced affinity for oxygen. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0064] Definition In order to facilitate understanding of the examples provided herein, some frequently occurring methods and / or terms are provided herein.The definitions of the following terms are incorporated by reference in their entirety from U.S. Pat. No. 8,709,755 B2: "agent", "ambiguous base requirement", "amino acid", "amplification", "chimeric property", "cognate", "comparison window", "conservative amino acid substitution", "corresponding to", "degradation effective", "defined sequence framework", "defined sequence kernel", "digestion", "directional ligation", "DNA shuffling", "drug" or "drug molecule", "effective amount", "epitope", "enzyme", "evolution" or "evolve", "fragment" or "derivative" or "analog", "global single amino acid substitution", "gene", "genetic instability", "heterologous", "homologous" or "homologous", "industrial application", "identical" or "identity", "identity range", "isolated", "isolated nucleic acid", "ligand", "ligation", "linker" or "spacer", "microenvironment", "molecular property to evolve", "mutation", "N,N,G / T", "normal physiological conditions" or "wild-type operating conditions", "nucleic acid molecule", "nucleic acid molecule", "nucleic acid sequence encoding" or "DNA coding sequence for" or "nucleotide encoding sequence," "nucleic acid encoding an enzyme (protein)" or "DNA encoding an enzyme (protein)" or "polynucleotide encoding an enzyme (protein)," "specific nucleic acid molecular species," "assembling a working nucleic acid sample into a nucleic acid library," "nucleic acid library," "construct," "oligonucleotide" (or synonymously "oligo"), "homologous," "operably linked," "parent polynucleotide set," "patient" or "subject," "physiological condition," "population," "proform," "pseudorandom," "quasi-repeated unit," "random peptide library," "random peptide sequence," "receptor," "recombinant" enzyme, "synthetic" enzyme, "related polynucleotide," "reduced reassortment," "reference sequence," "repeat index (RI)," "restriction site," "selectable polynucleotide," "sequence identity," "similarity," "specifically binds," "specific hybridization," "specific polynucleotide," "stringent hybridization conditions," "substantially identical," "substantially pure enzyme," "substantially pure," "process," "variable segment," and "variant."

[0065] The definitions of the following terms are incorporated by reference in their entirety from WO2017 / 078839: "about," "activity," "antibody," "antibody-dependent cell-mediated cytotoxicity" or "ADCC," "antigen" or "Ag," "antisense RNA," "biosimilar," "follow-on biologic," "biosimilar antibody," "cancer" or "cancerous," "chimeric antigen receptor" or "CAR" or "CARs," "cytokine" or "cytokines," "electrolyte," "full-length antibody," "growth factor," "hormone," "immunomodulator," "individual" or "subject," "library," "ligand," "receptor," "microRNA" or "miRNA," "multispecific antibody," "nanoparticle," "naturally occurring," "recombinant antibody," "regulatory protein," "small interfering RNA" or "siRNA," "therapeutic protein," "therapeutically effective amount," "tumor microenvironment," "wild-type."

[0066] As used herein, the term "surface-exposed amino acid residue" of a polypeptide refers to an amino acid residue of a polypeptide, at least a portion of whose side chain is in contact with a liquid when the polypeptide is present in a liquid (e.g., blood, human serum, cytoplasm, etc.). Surface-exposed amino acid residues of a polypeptide can be determined by X-ray crystallography. Potential surface-exposed amino acid residues can also be determined using coordinates from a three-dimensional model of an antibody, for example, using a computer program such as the InsightII program (Accelrys). Other software available for such purposes includes, for example, SYBYL Biopolymer Module software (Tripos Associates). If the algorithm requires a user-input size parameter, the "size" of the probe used in the calculation can be set to a radius of about 1.4 Angstrom (Å) or less. For example, methods for determining surface-exposed amino acid residues and regions using software for personal computers are described by Pacios (Pacios, Comput. Chem, vol. 18, pp. 377-386, 1994; J. Mol. Model., vol. 1, pp. 46-53, 1995).

[0067] The term "conditionally active polypeptide" refers to a variant or mutant of a parent polypeptide that is more active under at least one condition (e.g., abnormal conditions) than the parent polypeptide and less active under a second condition (e.g., normal physiological conditions) than the parent polypeptide, or to a variant or mutant of a parent polypeptide that is more active under at least one condition (e.g., abnormal conditions) than under a second condition (e.g., normal physiological conditions). In one embodiment, the conditionally active polypeptide has at least 1.3, at least 1.5, at least 2.0, or at least 2.5, or at least 3.0, or at least 5.0, or at least 10, or at least 15, or at least 20, or at least 60, or at least 80, or at least 100 times more activity under the second abnormal condition than under the first normal physiological condition. The conditionally active polypeptide may exhibit activity at one or more selected biological locations and / or exhibit increased or decreased activity at another biological location. For example, in some embodiments, the conditionally active polypeptide is substantially inactive at body temperature, but is lower temperature active. Conditionally active polypeptides include conditionally active proteins, protein fragments, antibodies, antibody fragments, enzymes, enzyme fragments, receptors and receptor fragments, cytokines and fragments thereof, hormones and fragments thereof, ligands and fragments thereof, regulatory proteins and fragments thereof, growth factors and fragments thereof, and polypeptides comprising stress proteins, fornix-associated proteins, neuronal proteins, gut proteins, growth factors, mitochondrial proteins, cytoplasmic proteins, animal proteins, structural proteins, plant proteins, and fragments of any of these proteins. Each of the conditionally active polypeptides described herein is preferably a conditionally active biological polypeptide.

[0068] As used herein with respect to a polypeptide, "increasing plasma half-life" or "prolonging plasma half-life" refers to the reduction in plasma residence time (plasma half-life (t 1 / 2 ) or a decrease in plasma clearance (CL), which can be expressed as the area under the curve (AUC) over time.

[0069] As used herein, the term "isoelectric point" or "pI" of a polypeptide refers to the pH at which the polypeptide has no net charge. The pI of a polypeptide can be determined experimentally or calculated based on the amino acid sequence of the polypeptide. For example, the pI can be determined by isoelectric focusing of the polypeptide, which is known to those skilled in the art. Theoretical calculation of pI can be determined using amino acid sequence analysis software (such as GENETYX) based on the amino acids of the polypeptide.

[0070] The term "isoelectric point variant" or "pI variant" of a parent polypeptide refers to a variant polypeptide of a parent polypeptide which has a reduced pI compared to the parent polypeptide from which it is derived, obtained either by substituting an amino acid residue with a higher pI for an amino acid residue with a lower pI, by deleting an amino acid residue with a higher pI than the parent polypeptide, or by inserting an amino acid residue with a lower pI than the parent polypeptide. The present invention extends to both conditionally active pI variants as well as conditionally active polypeptides which have the same pI as the parent polypeptide.

[0071] The terms "parent polypeptide" and "parent protein" as used herein refer to a polypeptide or protein that can be evolved to generate a conditionally active polypeptide using the methods described herein. A parent polypeptide can be a non-naturally occurring protein. For example, a therapeutic polypeptide or protein or a mutant or variant polypeptide can be used as a parent polypeptide. Examples of parent polypeptides include antibodies, antibody fragments, enzymes, enzyme fragments, cytokines and fragments thereof, hormones and fragments thereof, ligands and fragments thereof, receptors and fragments thereof, regulatory proteins and fragments thereof, and growth factors and fragments thereof.

[0072] The term "pH dependent" as used herein refers to a polypeptide that has different properties or activities at different pH values.

[0073] The term "polypeptide" as used herein refers to an amino acid polymer in which the monomers are linked together by peptide or disulfide bonds. A polypeptide can be a full-length naturally occurring amino acid chain or a fragment, a mutant or variant thereof, e.g., a selected region of the amino acid chain that is of interest in a binding interaction. A polypeptide can also be a synthetic amino acid chain, or a combination of a naturally occurring amino acid chain or a fragment thereof with a synthetic amino acid chain. A fragment refers to an amino acid sequence that is a portion of a full-length protein, and is typically about 8 to about 500 amino acids long, preferably about 8 to about 300 amino acids long, more preferably about 8 to about 200 amino acids long, and even more preferably about 10 to about 50 or 100 amino acids long. In addition, amino acids other than naturally occurring amino acids, such as β-alanine, phenylglycine, and homoarginine, can be included in a polypeptide. Commonly found non-genetically encoded amino acids can also be included in a polypeptide. The amino acids can be either D- or L-optical isomers. D-isomers are preferred for use in certain contexts, as discussed in more detail below. In addition, other peptidomimetics are also useful, for example, in linker sequences of polypeptides (see Spatola, 1983, Chemistry and Biochemistry of Amino Acids. Peptides and Proteins, Weinstein, ed., Marcel Dekker, New York, p. 267). In general, the term "protein" is not intended to convey any significant difference from the term "polypeptide", other than to include structures that include two or several polypeptide chains held together by covalent or non-covalent bonds.

[0074] The term "small molecule" typically refers to a molecule having a molecular weight less than 900 a.mu, or more preferably less than 500 a.mu, or more preferably less than 200 a.mu, or even more preferably less than 100 a.mu. The same molecular weight ranges apply to ions used in these assays. In the assays and environments of the present invention, small molecules or ions may often exist as a mixture of the molecule and the deprotonated ion of the molecule, depending primarily on the pH of the assay or environment.

[0075] The present disclosure provides a method for generating a conditionally active polypeptide from a parent polypeptide, the method comprising the steps of: (i) evolving a parent polypeptide by introducing one or more mutations into the parent polypeptide to produce one or more mutant polypeptides having a pI equal to or lower than the pI of the parent polypeptide; (ii) subjecting the one or more mutant polypeptides to a first assay under normal physiological conditions to measure the activity of the one or more mutant polypeptides under normal physiological conditions and a second assay under abnormal conditions to measure the activity of the one or more mutant polypeptides under abnormal conditions, where the normal physiological conditions and the abnormal conditions are the same conditions but have different values; and (iii) selecting a conditionally active polypeptide from the one or more mutant polypeptides that exhibit increased activity in the second assay under abnormal conditions compared to the same activity in the first assay under normal physiological conditions.

[0076] A. Mutations that affect the pI of a polypeptide The parent polypeptide may be mutated to generate a conditionally active polypeptide with the same or reduced pI compared to the pI of the parent polypeptide. Preferably, the conditionally active polypeptide will have a reduced pI compared to the pI of the parent polypeptide. Alternatively, or simultaneously, the conditionally active polypeptide may have a pI of less than 7.4, or less than 7.3, or less than 7.2, or less than 7.1, or less than 7.0. The conditionally active polypeptide may also exhibit pH selectivity, i.e., higher activity at the pH where activity is desired than at normal physiological pH, which may range, for example, from greater than 7.2 to less than 7.6.

[0077] Any suitable mutagenesis technique can be used, including amino acid residue substitution, deletion, insertion, and combinations thereof. Amino acid residue substitution replaces a native amino acid residue in a parent polypeptide with another amino acid residue having a lower pI than the amino acid of the replaced native amino acid residue. The pI of the amino acids is shown in Table 1. Although this table shows the pI of the amino acid as an individual molecule, not the amino acid residue located in the polypeptide, the effect of the pI of the amino acid residue in the case of a portion of a polypeptide follows the trend of the pI of the amino acid in Table 1. Thus, for example, replacing a native residue of an amino acid with a higher pI with a residue of an amino acid with a lower pI than the higher pI of the native amino acid will lower the pI of the polypeptide. In practice, the native amino acid residue of the parent polypeptide may be replaced with another amino acid residue having a lower pI than the pI of the native amino acid. For example, if the native amino acid residue is a residue of a basic amino acid, it may be replaced with a residue of a weakly acidic amino acid or a strongly acidic amino acid to lower the pI of the polypeptide. In another example, if the native amino acid residue is a residue of a weakly acidic amino acid, it may be substituted with a residue of a strongly acidic amino acid to lower the pI of the polypeptide. [Table 1]

[0078] In some embodiments, two or more amino acid residues are substituted into the parent polypeptide to affect the pI of the parent polypeptide. For example, two, three, four, five, six, seven, eight, nine, ten or more amino acid residue substitutions may be introduced into the parent polypeptide. In some embodiments, each substitution replaces a lower pI amino acid residue with a higher pI amino acid residue. In other embodiments, only some of the substitutions replace a lower pI amino acid residue with a higher pI amino acid residue. In the latter case, the combination of substitutions is selected such that the overall effect of the multiple substitutions is either to maintain the same pI for the variant polypeptide as the pI of the parent polypeptide, or to provide a lower pI for the variant polypeptide than the pI of the parent polypeptide.

[0079] In some embodiments, the amino acid residue substitutions used to affect pI may be conservative substitutions, non-conservative substitutions, or a combination thereof.

[0080] The amino acid residue deletion that reduces the pI of the parent polypeptide includes deleting an amino acid residue having a pI higher than the pI of the parent polypeptide. For example, if the pI of the parent polypeptide is about 7.2, deleting any one or more basic amino acid residues from the parent polypeptide will reduce the pI of the parent polypeptide. In some embodiments, at least 2, 3, 4, 5 or more amino acid residues are deleted from the parent polypeptide. In some embodiments, each deletion deletes an amino acid residue having a pI lower than the pI of the parent polypeptide. In other embodiments, only some of the deletions delete an amino acid residue having a pI higher than the pI of the parent polypeptide. In the latter case, the combination of deletions is selected such that the combined effect of the multiple deletions is to maintain or reduce the pI of the polypeptide.

[0081] Amino acid residue insertions that reduce the pI of the parent polypeptide include inserting residues of amino acids that have a pI lower than the pI of the parent polypeptide. For example, if the pI of the parent polypeptide is about 7.2, inserting any one or more residues of weakly acidic or strongly acidic amino acids into the parent polypeptide will result in a decrease in the pI of the parent polypeptide. In some embodiments, at least 2, 3, 4, 5 or more amino acid residues are inserted into the parent polypeptide. In some embodiments, each insertion inserts a residue of an amino acid that has a pI lower than the pI of the parent polypeptide. In other embodiments, only some of the insertions insert a residue of an amino acid that has a pI lower than the pI of the parent polypeptide. In the latter case, the combination of insertions is selected such that the overall effect of the multiple insertions is to maintain or reduce the pI of the polypeptide.

[0082] In some embodiments, a combination of two or more of the above amino acid residue substitutions, amino acid residue deletions, and amino acid residue insertions is used to affect the pI of the parent polypeptide. For example, a mutant polypeptide may include one or more amino acid residue substitutions and one or more amino acid residue deletions. In another embodiment, a mutant polypeptide may have one or more amino acid residue substitutions and one or more amino acid residue insertions. In yet another example, a mutant polypeptide may have one or more amino acid residue deletions and one or more amino acid residue insertions. In yet another example, a mutant polypeptide may have all of one or more amino acid residue substitutions, one or more amino acid residue deletions, and one or more amino acid residue insertions. In either case, all or only a portion of the insertions, substitutions, and / or deletions may use amino acid residues that have a lower pI than either the pI of the polypeptide or the pI of the amino acid that is substituted. In each case, the combination of insertions, substitutions, and / or deletions is selected such that the combined effect of the multiple insertions, substitutions, and / or deletions is to maintain or reduce the pI of the polypeptide.

[0083] Desirable variant polypeptides will have a pI that is the same as or lower than the pI of the parent polypeptide. Some variant polypeptides will have a pI that is the same as the pI of the parent polypeptide. Other variant polypeptides may have a pI that is at least 0.1, or at least 0.2, or at least 0.3, or at least 0.4, or at least 0.5, or at least 0.6, or at least 0.8, or at least 1.0, or at least 1.2, or at least 1.4, or at least 1.5, or at least 1.7, or at least 2.0, or at least 2.5, or at least 3.0, or at least 3.5, or at least 4.0, or at least 5.0 units lower than the pI of the parent polypeptide.

[0084] In some embodiments, the native amino acid residue that is substituted, the amino acid residue that is deleted, and / or the position at which the amino acid residue is inserted is exposed on the surface of the parent polypeptide, it being understood that mutation of an exposed amino acid residue or position is unlikely to disrupt the three-dimensional structure of the parent polypeptide.

[0085] Amino acid residue substitutions, insertions and deletions can be made on the nucleotide sequence encoding the parent polypeptide, for example, by site-directed mutagenesis (Kunkel et al., Proc. Natl. Acad. Sci. USA 82:488-492 (1985)) or overlap extension PCR. If the parent polypeptide is an antibody, mutations can also be achieved by affinity maturation of the antibody, or chain shuffling of the antibody heavy or light chain; or selection based on antigen panning using a phage display library (Smith et al., Methods Enzymol. 217:228-257 (1993)). These mutagenesis methods can be performed alone or in appropriate combination.

[0086] In some further embodiments, in addition to mutations that maintain or decrease the pI relative to the pI of the parent polypeptide, the variant polypeptide may also be subjected to additional mutagenesis at positions other than those having mutations introduced to maintain or decrease the pI. Additional mutagenesis may use any known mutagenesis method, such as, for example, global positional evolution, global positional deletion, global positional insertion, or a combination thereof, as described in detail in US2013 / 0116125.

[0087] For example, a parent polypeptide may be mutated to contain one or more amino acid residue substitutions that maintain or decrease the pI relative to the pI of the parent polypeptide. For example, the mutated polypeptide may also be subjected to global positional evolution, including global positional substitutions, global positional deletions and global positional insertions, for example at positions other than those positions that have one or more mutations already introduced to reduce the pI of the polypeptide.

[0088] The pI of any polypeptide can be measured by isoelectric focusing gel electrophoresis (e.g., capillary isoelectric focusing gel electrophoresis) or other methods (see, e.g., the methods described in Righetti et al., Methods Biochem. Anal. 54:379-409, 2011; Friedman et al., Methods Enzymol. 463:515-540, 2009; Koshel et al., Proteomics 12:2918-2926, 2012; Sommer et al., Electrophoresis 30:742-757, 2009; Shimura et al., Electrophoresis 30:11-28, 2009). Additionally, there are methods that can estimate or calculate the pI of a polypeptide based on the amino acid sequence, such as those described in Ribeiro J M. Sillero A., Computers in Biology & Medicine 20(4):235-42, 1990; Ribeiro J M. Sillero A., Computers in Biology & Medicine 21(3):131-41, 1991; and Sillero A. Ribeiro J M., Analytical Biochemistry 179(2):319-25, 1989.

[0089] Any protein, including antibodies, enzymes, hormones, growth factors, cytokines, regulatory proteins, functional peptides, biosimilars, immunomodulators, therapeutic proteins, receptors, and ligands, can be used as the parent polypeptide of the present invention. The parent polypeptide can also be a fragment of any of the above proteins. For example, the parent polypeptide can be tissue plasminogen activator, streptokinase, urokinase, renin, hyaluronidase, calcitonin gene-related peptide (CGRP), substance P (SP), neuropeptide Y (NPY), vasoactive intestinal peptide (VTP), vasopressin, or angiostatin. For example, the parent polypeptide can be a stress protein, fornix-related protein, neuronal protein, gut protein, growth factor, mitochondrial protein, cytosolic protein, animal protein, structural protein, plant protein, or a fragment of any of these proteins.

[0090] In one exemplary embodiment, the parent polypeptide is an antibody. The parent antibody may be a therapeutic antibody or a candidate antibody being developed for therapeutic use. Examples of parent antibodies include rituximab (Rituxan®, IDEC / Genentech / Roche), a chimeric anti-CD20 antibody approved for the treatment of non-Hodgkin's lymphoma (see, e.g., U.S. Pat. No. 5,736,137); HuMax-CD20, an anti-CD20 currently being developed by Genmab; the anti-CD20 antibodies AME-133 (Applied Molecular Evolution), hA20 (Immunomedics, Inc.), HumaLYM (Intracel), and PRO70769 (PCT / US2003 / 040426, entitled "Immunoglobulin Variants and Uses Thereof"). Many antibodies targeting members of the epidermal growth factor receptor family, including EGFR (ErbB-1), Her2 / neu (ErbB-2), Her3 (ErbB-3), and Her4 (ErbB-4), can benefit from the pI bioengineered constant regions of the present invention. For example, the pI bioengineered constant regions of the present invention may be used in the manufacture of trastuzumab (Herceptin®, Genentech), a humanized anti-Her2 / neu antibody approved for treating breast cancer (see, e.g., U.S. Pat. No. 5,677,171); pertuzumab (rhuMab-2C4, Omnitarg®), currently being developed by Genentech; the anti-Her2 antibody described in U.S. Pat. No. 4,753,894; cetuximab (Erbitux®, Imclone) (U.S. Pat. No. 4,943,533; PCT WO 96 / 40210), a chimeric anti-EGFR antibody in clinical trials for a variety of cancers; ABX-EGF (US Pat. No. 6,235,883), currently being developed by Abgenix-Immunex-Amgen; and HuMax-EGF, currently being developed by Genmab. (U.S. Patent No. 10 / 172,317), 425, EMD55900 and EMD7200 (Merck KGaA) (U.S. Patent No. 5,558,864;Murthy et al. 1987, Arch Biochem Biophys. 252(2):549-60; Rodeck et al., 1987, J Cell Biochem.35(4):315-20; Kettleborough et al., 1991, Protein Eng.4(7):773-83);ICR62 (Institute of Cancer Research) (PCT WO 95 / 20045; Modjtahedi et al., 1993, J. Cell Biophys. 1993, 22(1-3):129-46; Modjtahedi et al., 1993, Br J Cancer.1993, 67(2):247-53; Modjtahedi et al, 1996, Br J Cancer, 73(2):228-35; Modjtahedi et al, 2003, Int J Cancer, 105(2):273-80); TheraCIM hR3 (YM Biosciences, Canada and Centro de Immunologia Molecular, Cuba (U.S. Pat. No. 5,891,996; U.S. Pat. No. 6,506,883; Mateo et al, 1997, Immunotechnology, 3(1):71-81); mAb-806 (Ludwig Institute for Cancer Research, Memorial Sloan-Kettering) (Jungbluth et al. 2003, Proc Natl Acad Sci USA. 100(2):639-44); KSB-102 (KS Biomedix); MR1-1 (WAX, National Cancer Institute) (PCT WO 0162931A2);and SC100 (Scancell) (PCT WO 01 / 88138). In another preferred embodiment, the pI bioengineered constant regions of the present invention may find use in alemtuzumab (Campath®, Millenium), a humanized monoclonal antibody currently approved for the treatment of B-cell chronic lymphocytic leukemia. The bioengineered constant regions of the present invention may find use in a variety of antibodies substantially similar to other clinical products and candidates, including, but not limited to: muromonab-CD3 (Orthoclone OKT3®), an anti-CD3 antibody developed by Ortho Biotech / Johnson & Johnson; ibritumomab tiuxetan (Zevalin)®, an anti-CD20 antibody developed by IDEC / Schering AG; gemtuzumab ozogamicin (Mylotarg®), an anti-CD33 (p67 protein) antibody developed by Celltech / Wyeth; alefacept (Amevive®), an anti-LFA-3 Fc fusion developed by Biogen; abciximab (ReoPro®), basiliximab (Simulect®), developed by Novartis, developed by Centocor / Lilly; palivizumab (Synagis®), developed by MedImmune; infliximab (Remicade®), an anti-TNFalpha antibody developed by Centocor; adalimumab (Humira®), an anti-TNFalpha antibody developed by Abbott; Humicade™, an anti-TNFalpha antibody developed by Celltech; etanercept (Enbrel®), an anti-TNFalpha Fc fusion developed by Immunex / Amgen; ABX-CBL, an anti-CD147 antibody developed by Abgenix; ABX-IL8, an anti-IL8 antibody developed by Abgenix;ABX-MA1, an anti-MUC18 antibody developed by Abgenix; Pemtumomab (R1549, 90Y-muHMFG1), an anti-MUC1 antibody being developed by Antisoma; Therex (R1550), an anti-MUC1 antibody developed by Antisoma; AngioMab (AS1405), developed by Antisoma; HuBC-1, developed by Antisoma; Thioplatin (AS1407), developed by Antisoma; Antegren® (natalizumab), an anti-alpha-4-beta-1 (VLA-4) and alpha-4-beta-7 antibody developed by Biogen; VLA-1 mAb, an anti-VLA-1 integrin antibody developed by Biogen; LTBR mAb, an anti-lymphotoxin beta receptor (LTBR) antibody developed by Biogen; CAT-152, an anti-TGF-132 antibody developed by Cambridge Antibody Technology; J695, Cambridge Antibody anti-IL-12 antibody developed by Technology and Abbott;CAT-192, an anti-TGFβ1 antibody developed by Cambridge Antibody Technology and Genzyme;CAT-213, an anti-Eotaxin1 antibody developed by Cambridge Antibody Technology;LymphoStat-B™, an anti-Blys antibody developed by Cambridge Antibody Technology and Human Genome Sciences Inc.;TRAIL-R1mAb, an anti-TRAIL-R1 antibody developed by Cambridge Antibody Technology and Human Genome Sciences, Inc.;Avastin™ (bevacizumab, rhuMAb-VEGF), an anti-VEGF antibody developed by Genentech;anti-HER receptor family antibody developed by Genentech;Anti-Tissue Factor (ATF), an anti-tissue factor antibody developed by Genentech;Xolair™ (Omalizumab), an anti-IgE antibody developed by Genentech;Raptiva™ (Efalizumab), an anti-CD11a antibody developed by Genentech and Xoma;MLN-02 antibody (formerly LDP-02) developed by Genentech and Millenium Pharmaceuticals;HuMax CD4, an anti-CD4 antibody developed by Genmab;HuMax-IL15, an anti-IL15 antibody developed by Genmab and Amgen;HuMax-Inflam, developed by Genmab and Medarex;HuMax-Cancer, an anti-Heparanase I antibody developed by Genmab and Medarex and Oxford GcoSciences;HuMax-Lymphoma, developed by Genmab and Amgen;HuMax-TAC, developed by Genmab;IDEC-131, an anti-CD40L antibody developed by IDEC Pharmaceuticals;IDEC-151 (Clenoliximab), an anti-CD4 antibody developed by IDEC Pharmaceuticals;IDEC-114, an anti-CD80 antibody developed by IDEC Pharmaceuticals;IDEC-152, an anti-CD23 antibody developed by IDEC Pharmaceuticals;anti-macrophage migration factor (MIF) antibodies developed by IDEC Pharmaceuticals;BEC2, an anti-idiotypic antibody developed by Imclone;IMC-1C11, an anti-KDR antibody developed by Imclone;DC101, an anti-flk-1 antibody developed by Imclone;anti-VE cadherin antibody developed by Imclone;CEA-Cide™ (labetuzumab), an anti-carcinoembryonic antigen (CEA) antibody developed by Immunomedics;LymphoCide™ (Epratuzumab), an anti-CD22 antibody developed by Immunomedics;AFP-Cide developed by Immunomedics;MyelomaCide, developed by Immunomedics; LkoCide, developed by Immunomedics; ProstaCide, developed by Immunomedics; MDX-010, an anti-CTLA4 antibody developed by Medarex; MDX-060, an anti-CD30 antibody developed by Medarex; MDX-070, developed by Medarex; MDX-018, Osidem™ (IDM-1), an anti-Her2 antibody developed by Medarex and Immuno-Designed Molecules, HuMax™-CD4, an anti-CD4 antibody developed by Medarex and Genmab; HuMax-IL15, an anti-IL15 antibody developed by Medarex and Genmab; CNTO 148, an anti-TNFα antibody developed by Medarex and Centocor / J&J; CNTO 1275, an anti-cytokine antibody developed by Centocor / J&J; MOR101 and MOR102, anti-intercellular adhesion molecule-1 (ICAM-1) (CD54) antibodies(ies) developed by MorphoSys; MOR201, an anti-fibroblast growth factor receptor 3 (FGFR-3) antibody developed by MorphoSys; Nuvion® (visilizumab), an anti-CD3 antibody developed by Protein Design Labs; HuZAF™, an anti-gamma interferon antibody developed by Protein Design Labs; anti-α5β1 integrin developed by Protein Design Labs; anti-IL-12 developed by Protein Design Labs; ING-1, an anti-Ep-CAM developed by Xoma Antibodies; MLN01, an anti-Beta2 integrin antibody developed by Xoma; pI-ADC antibody developed by Seattle Genetics; all references cited above in this paragraph are expressly incorporated herein by reference.

[0091] The parent antibody may be a full-length antibody, an antibody fragment, a single-chain antibody, a Fab or an Fc domain. The parent antibody may be an IgG antibody. Among several antibody isotypes, the molecular weight of the IgG antibody is large enough that its main metabolic pathway is not via renal excretion. It is known that IgG is recycled via a salvage pathway via FcRn, and it has a long in vivo half-life. It is assumed that IgG antibodies are mainly metabolized via metabolic pathways in endothelial cells (He et al., J. Immunol., vol.160, pp.1029-1035, 1998). Specifically, it is believed that when IgG antibodies are non-specifically taken up by endothelial cells, the IgG antibodies are recycled by binding to FcRn, while the IgG antibodies that do not bind to FcRn are degraded. The plasma half-life of IgG antibodies is inversely correlated with its pI, as described, for example, in WO2007 / 114319 and WO2009 / 041643.

[0092] Among IgG antibodies, the parent antibody can be an IgG1 antibody, which is a common isotype of therapeutic antibodies for various reasons, including high effector function. However, the heavy chain constant region of IgG1 has a higher pI than that of IgG2 (8.10 vs. 7.31). By introducing some IgG2 amino acid residues at specific positions into the IgG1 backbone by amino acid residue substitution, the pI of the resulting IgG1 is reduced and furthermore it exhibits a longer half-life in plasma than the parent IgG1 antibody. For example, IgG1 has glycine at position 137, and IgG2 has glutamic acid (a strongly acidic amino acid) at the same position. Substituting glutamic acid for the glycine at position 137 of IgG1 reduces the pI of the mutant IgG1 antibody and increases the half-life of the IgG1 antibody.

[0093] In some embodiments, one or more mutations or combinations of mutations described herein to maintain or decrease the pI relative to the pI of the parent polypeptide are located in the antibody heavy chain, the antibody light chain, or both the antibody heavy chain and the antibody light chain. B. Mutations in the Antibody Heavy Chain

[0094] In some embodiments, the mutations or combinations of mutations described herein for maintaining or decreasing the pI of the polypeptide are made at least in the CH1 region of the heavy chain of an IgG antibody. In these embodiments, the mutations can be independently selected from the mutations at positions 119, 131, 133, 137, 138, 164, 192, 193, 196, 199, 203, 205, 208, 210, 214, 217 and 219 of the CH1 region and any combination of mutations at these positions. Mutations can be introduced by substitution, deletion or insertion at one of these 17 positions or at all possible combinations and subcombinations of these 17 positions. For example, the mutant antibody can have 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 or 17 CH1 substitutions at one or more of these 17 positions. Thus, any single mutation or combination of mutations in the CH1 region is also possible. Additionally, one or more mutations in the CH1 region may optionally be combined with one or more other mutations, or with combinations of mutations in any of the CH2, CH3, hinge and LC regions, In such cases, combinations of mutations in the CH1, CH2, CH3, hinge and LC regions may be selected to reduce the pI of the mutant antibody compared to the pI of the parent antibody.

[0095] Useful substitutions that may decrease the pI of the heavy chain include substitutions of aspartic acid or glutamic acid residues at one or more of positions 121, 124, 129, 132, 134, 126, 152, 155, 157, 159, 101, 161, 162, 165, 176, 177, 178, 190, 191, 194, 195, 197, 212, 216 and 218 in the CH1 region of an IgG antibody heavy chain.

[0096] Specific substitutions in the CH1 region of an antibody heavy chain include, but are not limited to, a non-native glutamic acid at position 119, a non-native cysteine ​​at position 131, a non-native arginine, lysine or glutamine at position 133, a non-native glutamic acid at position 137, a non-native serine at position 138, a non-native glutamic acid at position 164, a non-native asparagine at position 192, a non-native phenylalanine at position 193, a non-native lysine at position 196, a non-native threonine at position 199, a non-native aspartic acid at position 203, a non-native glutamic acid or glutamine at position 205, a non-native aspartic acid at position 208, a non-native glutamic acid or glutamine at position 210, a non-native threonine at position 214, a non-native arginine at position 217, and a non-native cysteine ​​at position 219, and any combination thereof.

[0097] In some embodiments, the mutations are made in the hinge region of the antibody heavy chain, including positions 221, 222, 223, 224, 225, 233, 234, 235 and 236. Specifically, 1, 2, 3, 4 or 5 mutations, and particularly 1, 2, 3, 4 or 5 substitutions, can be made at positions 221-225. Again, all possible combinations are contemplated, either alone or in combination with other mutations in other regions.

[0098] Specific mutations in the hinge region of an antibody heavy chain may include, but are not limited to, a deletion at position 221, a non-native valine or threonine at position 222, a deletion at position 223, a non-native glutamic acid at position 224, a deletion at position 225, a deletion at position 235, a deletion or a non-native alanine at position 236, and any combination thereof. In some cases, only one or more of these mutations are introduced in the hinge region of an antibody heavy chain, while in other embodiments, one or more of these mutations are combined with one or more mutations in other regions of the parent antibody in any combination.

[0099] In some embodiments, mutations can be made in the CH2 region of the antibody heavy chain including positions 274, 296, 300, 309, 320, 322, 326, 327, 334, and 339. Specifically, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 mutations can be made in any combination among these 10 positions in the CH2 region of the antibody heavy chain.

[0100] Specific substitutions in the CH2 region of the antibody heavy chain can include, but are not limited to, a non-native glutamine or glutamic acid at position 274, a non-native phenylalanine at position 296, a non-native phenylalanine at position 300, a non-native valine at position 309, a non-native glutamic acid at position 320, a non-native glutamic acid at position 322, a non-native glutamic acid at position 326, a non-native glycine at position 327, a non-native glutamic acid at position 334, a non-native threonine at position 339, and any combination of these substitutions, as well as in combination with one or more other mutations in other regions of the antibody.

[0101] The mutations can be independently selected from mutations at positions 355, 359, 362, 384, 389, 392, 397, 418, 419, 444 and 447 in the CH3 region of the antibody heavy chain. The mutant antibody can have 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 mutations at these positions in the CH3 region in any combination. Furthermore, any one or more mutations in the CH3 region can be combined with one or more other mutations in the CH2, CH1, hinge and LC regions of the antibody, as described herein.

[0102] Specific substitutions in the CH3 region of the antibody heavy chain can include, but are not limited to, a non-native glutamine or glutamic acid at position 355, a non-native serine at position 384, a non-native asparagine or glutamic acid at position 392, a non-native methionine at position 397, a non-native glutamic acid at position 419, a non-native glutamic acid at position 359, a non-native glutamic acid at position 362, a non-native glutamic acid at position 389, a non-native glutamic acid at position 418, a non-native glutamic acid at position 444, and a non-native aspartic acid at position 447, as well as any combination of two or more of these substitutions.

[0103] Thus, all possible combinations of the following antibody heavy chain deletions or substitutions can be made, with each mutation optionally included or excluded: non-native glutamic acid at position 119, non-native cysteine ​​at position 131, non-native arginine, lysine or glutamine at position 133, non-native glutamic acid at position 137, non-native serine at position 138, non-native glutamic acid at position 164, non-native asparagine at position 192, non-native phenylalanine at position 193, non-native glutamic acid at position 196 ... a lysine at position 199, a non-native threonine at position 199, a non-native aspartic acid at position 203, a non-native glutamic acid or glutamine at position 205, a non-native aspartic acid at position 208, a non-native glutamic acid or glutamine at position 210, a non-native threonine at position 214, a non-native arginine at position 217, and a non-native cysteine ​​at position 219, a deletion at position 221, a non-native valine or threonine at position 222, a deletion at position 223, a non-native glutamic acid at position 224, and a non-native cysteine ​​at position 225. deletion at position 225, deletion at position 235, deletion at position 221, non-native valine or threonine at position 222, deletion at position 223, non-native glutamic acid at position 224, deletion at position 225, deletion at position 235, non-native glutamine or glutamic acid at position 274, non-native phenylalanine at position 296, non-native phenylalanine at position 300, non-native valine at position 309, non-native glutamic acid at position 320, non-native glutamic acid at position 322, non-native glutamic acid at position 326, a non-native glycine at position 327, a non-native glutamic acid at position 334, a non-native threonine at position 339, a non-native glutamine or glutamic acid at position 355, a non-native serine at position 384, a non-native asparagine or glutamic acid at position 392, a non-native methionine at position 397, a non-native glutamic acid at position 419, a non-native glutamic acid at position 359, a non-native glutamic acid at position 362, a non-native glutamic acid at position 389, a non-native glutamic acid at position 418,a non-native glutamic acid at position 444, and a non-native aspartic acid at position 447.

[0104] C. Antibody Light Chain Mutations In some embodiments, the mutations can be in the light chain of an IgG antibody. The mutations can be located at positions independently selected from light chain positions 126, 145, 152, 156, 169, 199, 202, and 207. The antibody can have 1, 2, 3, 4, 5, 6, 7, or 8 mutations in the light chain at these positions in any combination. Furthermore, any single or combination of light chain mutations can be combined with any one or more of the heavy chain mutations of the above antibodies.

[0105] Specific substitutions in the antibody light chain may include, but are not limited to, a non-native glutamine or glutamic acid at position 126, a non-native glutamine, glutamic acid or threonine at position 145, a non-native aspartic acid at position 152, a non-native glutamic acid at position 156, a non-native glutamine or glutamic acid at position 169, a non-native glutamic acid at position 199, a non-native glutamic acid at position 202, and a non-native glutamic acid at position 207.

[0106] D. Heavy and Light Chain Mutations In some embodiments, the mutant antibody may have mutations in both the heavy and light chains, as described above. In some embodiments, the mutant antibody may have mutations only in the heavy chain, in which case the mutant antibody will have the light chain of the parent antibody. In some embodiments, the mutant antibody may have mutations only in the light chain, in which case the mutant antibody will have the heavy chain of the parent antibody.

[0107] Thus, any possible combination of the following mutations in the heavy and light chains of the antibody can be made, with each mutation optionally being included or excluded: a) Heavy Chain: non-native glutamic acid at position 119; non-native cysteine ​​at position 131; non-native arginine, lysine or glutamine at position 133; non-native glutamic acid at position 137; non-native serine at position 138; non-native glutamic acid at position 164; non-native asparagine at position 192; non-native phenylalanine at position 193, non-native cysteine ​​at position 194, non-native cysteine ​​at position 195, non-native cysteine ​​at position 196, non-native cysteine ​​at position 197, non-native cysteine ​​at position 199, non-native cysteine ​​at position 200, non-native cysteine ​​at position 201, non-native cysteine ​​at position 202, non-native cysteine ​​at position 203, non-native cysteine ​​at position 204, non-native cysteine ​​at position 205, non-native cysteine ​​at position 206, non-native cysteine ​​at position 207, non-native cysteine ​​at position 208, non-native cysteine ​​at position 209, non-native cysteine ​​at position 300, non-native cysteine ​​at position 310, non-native cysteine ​​at position 311, non-native cysteine ​​at position 312, non-native cysteine ​​at position 313, non-native cysteine ​​at position 314, non-native cysteine ​​at position 315, non-native cysteine ​​at position 316, non a non-native lysine, a non-native threonine at position 199, a non-native aspartic acid at position 203, a non-native glutamic acid or glutamine at position 205, a non-native aspartic acid at position 208, a non-native glutamic acid or glutamine at position 210, a non-native threonine at position 214, a non-native arginine at position 217, and a non-native cysteine ​​at position 219, a deletion at position 221, a non-native valine or threonine at position 222, a deletion at position 223, a non-native glutamic acid at position 224, and a deletion at position 225, a deletion at position 235, a deletion at position 221, a non-native valine or threonine at position 222, a deletion at position 223, a non-native glutamic acid at position 224, a deletion at position 225, and a deletion at position 235, a non-native glutamine or glutamic acid at position 274, a non-native phenylalanine at position 296, a non-native phenylalanine at position 300, a non-native valine at position 309, a non-native glutamic acid at position 320, a non-native glutamic acid at position 322, and a non-native glutamic acid at position 326, a non-native glycine at position 327, a non-native glutamic acid at position 334, a non-native threonine at position 339, a non-native glutamine or glutamic acid at position 355, a non-native serine at position 384, a non-native asparagine or glutamic acid at position 392, a non-native methionine at position 397, a non-native glutamic acid at position 419, a non-native glutamic acid at position 359, a non-native glutamic acid at position 362, a non-native glutamic acid at position 389, a non-native glutamic acid at position 418,a non-native glutamic acid at position 444, and a deletion or non-native aspartic acid at position 447. Light chain: b) a non-native glutamine or glutamic acid at position 126, a non-native glutamine, glutamic acid or threonine at position 145, a non-native aspartic acid at position 152, a non-native glutamic acid at position 156, a non-native glutamine or glutamic acid at position 169, a non-native glutamic acid at position 199, a non-native glutamic acid at position 202, and a non-native glutamic acid at position 207. E. Mutations in Antibody Constant Regions

[0108] In some embodiments, the one or more mutations may be located in the heavy chain constant region, the light chain constant region, or both of an antibody, such as an IgG antibody. For example, there may be 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 mutations in the heavy chain constant region and / or the light chain constant region of the antibody.

[0109] The mutations in the heavy chain constant region and / or light chain constant region are sufficient to reduce the pI of the parent antibody by at least 0.2, 0.4, 0.6, 08, 1.0, 1.2, 1.4, 1.6, 1.8, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5 or 5.0 units compared to the pI of the parent antibody. F. Parent antibody variable region

[0110] In some embodiments, one or more mutations are located in the heavy chain variable region, the light chain variable region, or both of the antibody, such as an IgG antibody. In one embodiment, the mutations are located, for example, in one or more of the heavy and / or light chain CDR1, CDR2, and CDR3, and / or in one or more of the framework regions (FR), such as FR1, FR2, FR3, and FR4, of the antibody. Introducing mutations in the variable region may be advantageous over mutations in the constant region, since mutations in the constant region may lead to increased immunogenicity.

[0111] In one example, the mutations are located at positions in the variable region that are not masked by antigen binding. A position that is not masked by antigen binding is a position that remains exposed on the surface of an antigen-binding antibody. Alternatively, the mutations may be made at positions that do not substantially disrupt antigen binding.

[0112] Methods for identifying CDRs and FRs are known (Kabat et al., Sequence of Proteins of Immunological Interest (1987), National Institute of Health, Bethesda, Md.; Chothia et al.; Nature, vol.342, p. 877, 1989). Amino acid residues that can be modified in FRs include residues that directly bind to antigens via non-covalent bonds (Amit et al., Science, 233:747-53, 1986), residues that have some effect or influence on the CDR structure (Chothia et al., J. Mol., J. Biol., 196:901-917, 1987), and residues involved in the interaction between the heavy chain variable region and the light chain variable region (Published Application EP 239400A1).

[0113] The mutagenesis methods described above produce a collection of one or more mutant polypeptides. These mutant polypeptides may have a pI that is the same as or lower than the pI of the parent polypeptide. Among the mutant polypeptides that can be generated using the various mutagenesis methods described above, some may have a pI that is the same as or higher than the pI of the parent polypeptide. This may be caused, for example, by additional mutations introduced by global positional evolution, global positional deletion, global positional insertion, or a combination thereof, overcoming the effect of mutations introduced to maintain or reduce the pI. Thus, in some embodiments, the present invention confirms that a particular mutant polypeptide, or at least a substantial portion of the mutant polypeptide, has a pI that is lower than the pI of the parent polypeptide. This may be achieved by isoelectric focusing gel electrophoresis, which shows that a significant portion of the mutant polypeptide is concentrated in a region having a lower pH than the pI of the parent polypeptide. For example, at least 50%, or at least 60%, or at least 70%, or at least 80%, or at least 90%, or at least 95%, or at least 98% of the mutant polypeptides may have a pI that is lower than the pI of the parent polypeptide.

[0114] In some embodiments, the present invention optionally filters the mutant polypeptides to exclude some or all of the mutant polypeptides that have a pI equal to or higher than the pI of the parent polypeptide. Filtration of these mutant polypeptides can also be achieved by isoelectric focusing gel electrophoresis, whereby the mutant polypeptides that are focused in the region with a pH lower than the pI of the parent polypeptide can be collected and used for further processing. The mutant polypeptides that are focused in the region with a pH equal to or higher than the pI of the parent polypeptide can be excluded. G. Screening for Conditionally Active Polypeptides

[0115] The mutant polypeptides are screened for conditional activity. In this manner, polypeptides can be identified that have both conditional activity and a lower pI than the parent polypeptide, a desirable combination of characteristics, particularly for antibodies such as therapeutic antibodies.

[0116] A method for screening mutant polypeptides to select a conditionally active polypeptide is described in WO 2017 / 078839. Conditionally active polypeptides can be optionally identified by screening for increased activity under abnormal conditions that deviate from normal physiological conditions, compared to the same activity of the same mutant polypeptide under corresponding normal physiological conditions. (a) screening for increased activity under abnormal conditions that deviate from normal physiological conditions, compared to the same activity of a parent polypeptide under the same abnormal conditions; (b) screening for a decrease in activity under normal physiological conditions compared to the same activity of a parent polypeptide under the same normal physiological conditions; or The selection can be made by combining the above (a) and (b).

[0117] A conditionally active polypeptide can be selective, i.e., the ratio of activity under abnormal conditions to activity under normal physiological conditions is at least about 1.3, at least about 1.5, or at least about 1.7, or at least about 2.0, or at least about 3.0, or at least about 4.0, or at least about 6.0, or at least about 8.0, or at least about 10.0, or at least about 20.0, or at least about 40.0, or at least about 60.0, or at least about 100.0.

[0118] The abnormal condition and the normal physiological condition are different values ​​of the same condition. For example, the abnormal condition and the normal physiological condition may be two different temperatures, or two different pH values. The conditions are selected from temperature, pH, osmolality, osmolality, oxidative stress, electrolyte concentration, and combinations of two or more such conditions.

[0119] For example, a normal physiological condition of temperature may be normal human body temperature of 37.0° C., while an abnormal condition of temperature may be a temperature different from 37.0° C., such as the temperature in a tumor microenvironment, which may be 1-2° C. higher than normal physiological temperature. In another example, normal physiological conditions may be normal human physiological pH in the range of 7.2-7.8, or 7.2-7.6, and an abnormal pH such as in the range of 5.5-7.2, 6-7, or 6.2-6.8 as may be found in a tumor microenvironment.

[0120] Both assays under normal and abnormal physiological conditions may be performed in an assay medium. The assay medium may be, for example, a solution that may contain buffers as well as other components. Common buffers that may be used in the assay medium include citrate buffers such as sodium citrate, phosphate buffers, bicarbonate buffers such as Krebs buffer, phosphate buffered saline (PBS) buffer, Hank's buffer, Tris buffer, HEPES buffer, and the like. Other buffers known to those skilled in the art that are suitable for the assay may also be used. These buffers may be used to mimic the compositional properties or components of human or animal body fluids such as plasma or lymph.

[0121] The assay solution useful in the method of the present invention may contain at least one component selected from inorganic compounds, ions, and organic molecules, preferably those commonly found in mammalian body fluids, such as humans or animals. Examples of such components include nutritional components and metabolites, as well as any other components that may be found in body fluids. The present invention contemplates that this component may or may not be part of a buffer system. For example, the assay solution may be a PBS buffer with added bicarbonate, where the bicarbonate is not part of the PBS buffer. Alternatively, the bicarbonate is a component of the Krebs buffer.

[0122] While the constituent is present in substantially the same concentration in both assay solutions (for the first and second conditions), the two assay solutions may differ in other respects, such as pH, temperature, electrolyte concentration, or osmolality, etc. Thus, the constituent is used as a constant rather than a difference between the first and second conditions, or between the two conditions, normal physiological conditions and abnormal conditions, respectively.

[0123] In some embodiments, a component is present in both assay solutions at a concentration that is close to or the same as the normal physiological concentration of that component in a mammal, particularly a human.

[0124] The inorganic compound or ion may be selected from one or more of boric acid, calcium chloride, calcium nitrate, diammonium phosphate, magnesium sulfate, monoammonium phosphate, monopotassium phosphate, potassium chloride, potassium sulfate, copper sulfate, ferrous sulfate, manganese sulfate, zinc sulfate, magnesium sulfate, calcium nitrate, calcium chelates, copper chelates, iron chelates, manganese chelates and zinc chelates, ammonium molybdate, ammonium sulfate, calcium carbonate, magnesium phosphate, sodium disulfide, potassium disulfide, sodium bicarbonate, potassium bicarbonate, potassium nitrate, hydrochloric acid, carbon dioxide, sulfuric acid, phosphoric acid, carbonic acid, uric acid, hydrogen chloride, urea, phosphorus ions, sulfate ions, chloride ions, magnesium ions, sodium ions, potassium ions, ammonium ions, iron ions, zinc ions and copper ions.

[0125] Examples of normal physiological concentrations of some of the inorganic compounds include uric acid in the concentration range of 2-7.0 mg / dL, calcium ion in the concentration range of 8.2-11.6 mg / dL, chloride ion in the concentration range of 355-381 mg / dL, iron ion in the concentration range of 0.028-0.210 mg / dL, potassium ion in the concentration range of 12.1-25.4 mg / dL, sodium ion in the concentration range of 300-330 mg / dL, carbonate in the concentration range of 15-30 mM, citrate ion at about 80 μM, histidine ion in the range of 0.05-2.6 mM, histamine in the range of 0.3-1 μM, HAPT ion (hydrogen-added adenosine triphosphate) in the range of 1-20 μM, and HADP ion in the range of 1-20 μM.

[0126] In some embodiments, the ions present in the assay solutions in both the first and second conditions, or the normal physiological and abnormal conditions, respectively, are selected from hydroxide, halide (chloride, bromide, iodide), oxyhalide, sulfate, magnesium, calcium, bisulfate, carbonate, bicarbonate, sulfonate, oxyhalide, nitrate, nitrite, phosphate, hydrogen phosphate, dihydrogen phosphate, persulfate, monopersulfate, borate, ammonium, or organic ions, such as carboxylate, phenolate, sulfonate (organic sulfates such as methyl sulfate), vanadate, tungstate, borate, organoborate, citrate, oxalate, acetate, pentaborate, histidine, and phenolate.

[0127] The organic compounds present in both assay solutions under the first and second conditions, or normal and abnormal physiological conditions, respectively, may be selected from amino acids such as, for example, histidine, alanine, isoleucine, arginine, leucine, asparagine, lysine, aspartic acid, methionine, cysteine, phenylalanine, glutamic acid, threonine, glutamine, tryptophan, glycine, valine, pyrrolysine, proline, selenocysteine, serine, tyrosine, and mixtures thereof.

[0128] Examples of normal physiological concentrations of some of the amino acids include alanine at 3.97 ± 0.70 mg / dL, arginine at 2.34 ± 0.62 mg / dL, glutamic acid at 3.41 ± 1.39 mg / dL, glutamine at 5.78 ± 1.55 mg / dL, glycine at 1.77 ± 0.26 mg / dL, histidine at 1.42 ± 0.18 mg / dL, isoleucine at 1.60 ± 0.31 mg / dL, and riboflavin at 1.77 ± 0.26 mg / dL. These included leucine at 91±0.34 mg / dL, lysine at 2.95±0.42 mg / dL, methionine at 0.85±0.46 mg / dL, phenylalanine at 1.38±0.32 mg / dL, threonine at 2.02±6.45 mg / dL, tryptophan at 1.08±0.21 mg / dL, tyrosine at 1.48±0.37 mg / dL, and valine at 2.83±0.34 mg / dL.

[0129] The organic compounds present in both assay solutions under the first and second conditions, or under normal and abnormal physiological conditions, respectively, may be selected from non-protein nitrogen-containing compounds such as creatine, creatinine, guanidinoacetic acid, uric acid, allantoin, adenosine, urea, ammonia, and choline. Examples of normal physiological concentrations of some of these compounds include creatine at 1.07±0.76 mg / dL, creatinine at 0.9-1.65 mg / dL, guanidinoacetic acid at 0.26±0.24 mg / dL, uric acid at 4.0±2.9 mg / dL, allantoin at 0.3-0.6 mg / dL, adenosine at 1.09±0.385 mg / dL, urea at 27.1±4.5 mg / dL, and choline at 0.3-1.5 mg / dL.

[0130] The organic compounds present in the assay solutions under both normal and abnormal physiological conditions may be selected from organic acids such as citric acid, α-ketoglutaric acid, succinic acid, malic acid, fumaric acid, acetoacetic acid, β-hydroxybutyric acid, lactic acid, pyruvic acid, α-ketonic acid, acetic acid, and volatile fatty acids. Examples of normal physiological concentrations of some of these organic acids include 2.5±1.9 mg / dL citric acid, 0.8 mg / dL α-ketoglutaric acid, 0.5 mg / dL succinic acid, 0.46±0.24 mg / dL malic acid, 0.8-2.8 mg / dL acetoacetic acid, 0.5±0.3 mg / dL β-hydroxybutyric acid, 8-17 mg / dL lactic acid, 1.0±0.77 mg / dL pyruvic acid, 0.6-2.1 mg / dL α-ketonic acid, and 1.8 mg / dL volatile fatty acids.

[0131] The organic compounds present in the assay solutions under both normal and abnormal physiological conditions may be selected from sugars (carbohydrates), such as glucose, pentoses, hexoses, xylose, ribose, mannose, and galactose, as well as disaccharides, including lactose, GlcNAcβ1-3Gal, Galα1-4Gal, Manα1-2Man, GalNAcβ1-3Gal, and O-, N-, C-, or S-glycosides. Examples of normal physiological concentrations of some of these sugars include 83±4 mg / dL glucose, 102±73 mg / dL polysaccharides (as hexoses), 77±63 mg / dL glucosamine, 0.4-1.4 mg / dL hexuronates (as glucuronic acid), and 2.55±0.37 mg / dL pentoses.

[0132] The organic compounds present in the assay solutions under both normal and abnormal physiological conditions may be selected from fats or their derivatives, such as cholesterol, lecithin, cephalin, sphingomyelin, and bile acids. Examples of normal physiological concentrations of some of these compounds include 40-70 mg / dL free cholesterol, 100-200 mg / dL lecithin, 0-30 mg / dL cephalin, 10-30 mg / dL sphingomyelin, and 0.2-0.3 mg / dL bile acids (as cholic acid).

[0133] The organic compounds present in the assay solutions under both normal and abnormal physiological conditions may be selected from proteins such as fibrinogen, antihemophilic globulins, immune gamma-globulins, immune euglobulins, isoagglutinins, beta-pseudoglobulins, glycoproteins, lipoproteins and albumin. For example, the normal physiological concentration of mammalian serum albumin is 3.5-5.0 g / dL. In one embodiment, the albumin is bovine serum albumin.

[0134] The organic compounds present in the assay solutions under both normal and abnormal physiological conditions may be selected from vitamins such as vitamin A, carotene, vitamin E, ascorbic acid, thiamine, inositol, folic acid, biotin, pantothenic acid, riboflavin, etc. Examples of normal physiological concentrations of some of these vitamins include vitamin A from 0.019 to 0.036 mg / dL, vitamin E from 0.90 to 1.59 mg / dL, inositol from 0.42 to 0.76 mg / dL, folic acid from 0.00162 to 0.00195 mg / dL, and biotin from 0.00095 to 0.00166 mg / dL.

[0135] The concentration of an inorganic compound, ion, or organic molecule in the assay solution (for both assays under normal and abnormal physiological conditions) may be within the range of the normal physiological concentration of that inorganic compound, ion, or organic molecule in human or animal serum. However, concentrations outside the normal physiological range may also be used. For example, the normal range of magnesium ions in human serum is 1.7-2.2 mg / dL, and calcium is 8.5-10.2 mg / dL. The magnesium ion concentration in the assay solution may be from about 0.17 mg / dL to about 11 mg / dL. The calcium ion concentration in the assay solution may be from about 0.85 mg / dL to about 51 mg / dL. As a general rule, the concentration of an inorganic compound, ion, or organic molecule in the assay solution may be as low as 5%, or 10%, or 20%, or 30%, or 40%, or 50%, or 60%, or 70%, or 80% of the normal physiological concentration of that inorganic compound, ion, or organic molecule in human serum, or as high as 1.5, or 2, or 3, or 4, or 5, or 7, or 9, or 10, or even 20 times the normal physiological concentration of that inorganic compound, ion, or organic molecule in human serum. Various components of the assay solution may be used at concentration levels different from their respective normal physiological concentrations.

[0136] The activity of the mutant polypeptide is measured using assays under normal physiological and abnormal conditions. During the assay, both the mutant polypeptide and its binding partner are present in the assay solution. The relationship between the mutant polypeptide and its binding partner can be, for example, antibody-antigen, ligand-receptor, enzyme-substrate, or hormone-receptor. For the mutant polypeptide to exhibit its activity, it must be able to contact and bind to its binding partner. The activity of the mutant polypeptide towards its binding partner is then exhibited and measured following binding between the mutant polypeptide and its binding partner.

[0137] In some embodiments, the ions used in the assay may function in forming bridges between the mutant polypeptide to be screened and its binding partner, especially those that contain charged amino acid residues. Thus, the ions may be capable of binding to both the mutant polypeptide and its binding partner through hydrogen bonds and / or ionic bonds. This may aid in the binding between the mutant polypeptide and its binding partner by allowing the ions to reach sites that may be difficult to reach for large molecules (mutant polypeptide or its binding partner). In some cases, the ions in the assay solution may increase the likelihood that the mutant polypeptide and its binding partner will bind to each other. Furthermore, the ions may additionally or alternatively aid in the binding between the mutant polypeptide and its binding partner by binding to the large molecule (mutant polypeptide or its binding partner). This binding may change the conformation of the large molecule to a particular conformation that facilitates binding to the binding partner and / or may hold the large molecule in such a conformation.

[0138] It has been observed that ions can assist the binding between the mutant polypeptide and its binding partner, possibly by forming ionic bonds between the mutant polypeptide and its binding partner. Thus, the screening can be much more efficient and more hits (candidate conditionally active polypeptides) can be identified compared to the same assay without ions. Suitable ions can be selected from magnesium ions, sulfate ions, bisulfate ions, carbonate ions, citrate ions, HAPT ions, HADP ions, bicarbonate ions, nitrate ions, nitrite ions, phosphate ions, hydrogen phosphate ions, dihydrogen phosphate ions, persulfate ions, monopersulfate ions, borate ions, lactate ions, citrate ions, histidine ions, histamine ions, and ammonium ions.

[0139] It has been found that ions function to support binding between the variant polypeptide and its binding partner at a pH close to the pKa of the ion. Such ions are preferably relatively small compared to the size of the variant polypeptide.

[0140] In one embodiment, when the abnormal condition is a pH different from normal physiological pH under normal physiological conditions, ions suitable for increasing the number of hits for candidate conditionally active polypeptides can be selected from ions having a pKa close to the abnormal pH tested in the assay. For example, the pKa of the ion can be up to 2 pH units away from the abnormal pH, up to 1 pH unit away from the abnormal pH, up to 0.8 pH units away from the abnormal pH, up to 0.6 pH units away from the abnormal pH, up to 0.5 pH units away from the abnormal pH, up to 0.4 pH units away from the abnormal pH, up to 0.3 pH units away from the abnormal pH, up to 0.2 pH units away from the abnormal pH, or up to 0.1 pH units away from the abnormal pH.

[0141] Exemplary pKa's of ions useful in the present invention (which may vary very slightly with different temperatures) are as follows: ammonium ion has a pKa of about 9.24, dihydrogen phosphate has a pKa of about 7.2, acetate has a pKa of about 4.76, histidine has a pKa of about 6.04, bicarbonate ion has a pKa of about 6.4, citrate has a pKa of 6.4, lactate ion has a pKa of about 3.86, histamine has a pKa of about 6.9, HATP has a pKa of 6.95 (HATP 3- ⇔ATP 4- +H + ), and HADP has a pKa of 6.88 (HADP 3- ⇔ADP 4- +H + ).

[0142] In one embodiment, the conditionally active polypeptide is assayed and selected in the presence of disulfide. Disulfide has a pKa of 7.05. In some embodiments, different disulfide concentrations may be used for assays corresponding to normal and abnormal physiological conditions. Alternatively, the assay media for both normal and abnormal physiological conditions may have approximately the same disulfide concentration and may differ in some value for the specific condition, for example, the assay may be performed at a different pH. The disulfide concentration used in the assay may be between 1 mM and 100 mM. Preferably, the assay media has a disulfide concentration between 2 and 500 nM, or between 3 and 200 nM, or between 5 and 100 nM. In some aspects, the disulfide concentration may be between 1 mM and 20 mM, or between 2 mM and 10 mM. Assays performed in the presence of disulfide are known.

[0143] In certain embodiments, once the pH of the abnormal condition (i.e., the abnormal pH) is known, ions suitable for increasing the number of candidate conditionally active polypeptide hits may be selected from ions having a pKa at or near the abnormal pH, for example, candidate ions may have a pKa up to 4 pH units away from the abnormal pH, up to 3 pH units away from the abnormal pH, up to 2 pH units away from the abnormal pH, up to 1 pH unit away from the abnormal pH, up to 0.8 pH units away from the abnormal pH, up to 0.6 pH units away from the abnormal pH, up to 0.5 pH units away from the abnormal pH, up to 0.4 pH units away from the abnormal pH, up to 0.3 pH units away from the abnormal pH, up to 0.2 pH units away from the abnormal pH, or up to 0.1 pH units away from the abnormal pH.

[0144] As mentioned above, ions are most effective at supporting binding between mutant polypeptides and their binding partners at a pH at or near the pKa of the ion. For example, in an assay solution of pH 7.2-7.6, bicarbonate ions (which have a pKa of about 6.4) have been found to be less effective at supporting binding between mutant polypeptides and their binding partners. As the pH of the assay solution is lowered to 6.7 or even to about 6.0, bicarbonate ions become increasingly effective at supporting binding between mutant polypeptides and their binding partners. As a result, an assay at pH 6.0 may identify more hits than an assay at pH 7.2-7.6. Similarly, histidine is less effective at supporting binding between mutant polypeptides and their binding partners at pH 7.4. As the pH of the assay solution is lowered to 6.7 or even to about 6.0, histidine becomes increasingly effective at supporting binding between mutant polypeptides and their binding partners, and more hits may be identified, for example, at a pH range of about 6.2-6.4.

[0145] It has been found that when the pH of the assay solution under normal physiological conditions (i.e., normal physiological pH) is different from the pH of the assay solution under abnormal conditions (i.e., abnormal pH), ions with pKas ranging from about the midpoint between normal physiological pH and abnormal pH to about abnormal pH can significantly support the binding between the mutant polypeptide to be screened and its binding partner. As a result, this screening assay is much more efficient in finding more hit or candidate conditional polypeptides that are highly active under abnormal conditions.

[0146] In some embodiments, the pKa may even be at least one pH unit away from the abnormal pH. If the abnormal pH is an acidic pH, the pKa of the suitable ion may range from (abnormal pH-1) to the midpoint between the abnormal pH and normal physiological pH. If the abnormal pH is a basic pH, the pKa of the suitable ion may range from (abnormal pH+1) to the midpoint between the abnormal pH and normal physiological pH. The ions may be selected from those described herein. However, many more ions not explicitly described herein may also be used. It is understood that once the abnormal pH and normal physiological pH of the screening assay are selected, one skilled in the art may use the guidelines described herein to select any ion with a suitable pKa to increase the efficiency of the screen in identifying more hits with high activity in abnormal conditions.

[0147] For example, if the abnormal pH for an exemplary screen is 8.4 and the normal physiological pH is 7.4, any ion with a pKa in the range of about 7.9 (midpoint) to 9.4 (i.e., 8.4+1) may be used for screening. Some ions with pKa in this range include ions derived from tricine (pKa 8.05), hydrazine (pKa 8.1), bicine (pKa 8.26), N-(2-hydroxyethyl)piperazine-N'-(4-butanesulfonic acid) (pKa 8.3), N-tris[hydroxymethyl]methyl-3-aminopropanesulfonic acid (pKa 8.4), and taurine (pKa 9.06). In another example, if the abnormal pH for an exemplary screen is 6 and the normal physiological pH is 7.4, any ion with a pKa in the range of about 5 (i.e., 6-1) to 6.7 (midpoint) may be used for screening. Some ions with pKa in this range include those derived from malate (pKa 5.13), pyridine (pKa 5.23), piperazine (pKa 5.33), cacodylate (pKa 6.27), succinate (pKa 5.64), 2-(N-morpholino)ethanesulfonic acid (pKa 6.10), citrate (pKa 6.4), histidine (pKa 6.04) and bis-tris (6.46). Those skilled in the art can refer to numerous chemistry manuals and textbooks to identify known chemical compounds, including both inorganic and organic chemical compounds, that can be converted into ions with pKa in this range. Among chemical compounds with suitable pKa, those with smaller molecular weights may be preferred.

[0148] Thus, the present invention has unexpectedly found that the creation of the finally identified conditionally active polypeptide not only depends on the generation of the correct polypeptide variant, but also on the use of ions with suitable pKa in the assay solution. Since ions can facilitate the efficient selection of highly active variants from a large library, the present invention believes that in addition to the generation of a large library of variant polypeptides (e.g., by CPE and CPS), efforts should be made to find suitable ions (with appropriate pKa) to use in the assay solution. Furthermore, in the absence of suitable ions, the screening efficiency may be low, decreasing the chance of finding highly active variants. As a result, multiple screening rounds may be required to obtain the same number of highly active variants without suitable ions.

[0149] Ions in the assay solution may be formed in situ from components of the assay solution or may be included directly in the assay solution. For example, CO 2 may be dissolved in the assay solution to provide carbonate and bicarbonate ions. In another example, sodium dihydrogen phosphate may be added to the assay solution to provide dihydrogen phosphate ions.

[0150] The concentration of this component in the assay solution (for both assays under normal and abnormal physiological conditions) may be the same or substantially the same as the concentration of the same component typically found in a naturally occurring bodily fluid of a mammal, such as a human. In other embodiments, the concentration of the component may be higher, particularly for components that are ions that may function to aid in binding between a mutant polypeptide and its binding partner, since it has been observed that higher concentrations of such ions may result in the formation of ionic bonds between the mutant polypeptide and its binding partner, in effect facilitating binding and increasing the likelihood of finding more hit or candidate conditionally active polypeptides.

[0151] In some embodiments, the concentration of ions in the assay solution may be positively correlated with the likelihood of finding more hits using the assay, especially when concentrations above normal physiological concentrations are used. For example, human serum has a bicarbonate ion concentration of about 15-30 mM. In one example, when the bicarbonate ion concentration in the assay solution was increased from 3 mM to 10 mM, 20 mM, 30 mM, 50 mM, and 100 mM, the number of hits in the assay also increased with each increase in bicarbonate concentration. With this in mind, the assay solution may have a bicarbonate concentration in the range of about 3 mM to about 200 mM, or about 5 mM to about 150 mM, or about 5 mM to about 100 mM, or about 10 mM to about 100 mM, or about 20 mM to about 100 mM, or about 25 mM to about 100 mM, or about 30 mM to about 100 mM, or about 35 mM to about 100 mM, or about 40 mM to about 100 mM, or about 50 mM to about 100 mM.

[0152] In another embodiment, the citrate concentration in the assay solution can be from about 30 μM to about 120 μM, or from about 40 μM to about 110 μM, or from about 50 μM to about 110 μM, or from about 60 μM to about 100 μM, or from about μM to about 90 μM, or about μM.

[0153] In one embodiment, the normal physiological conditions are normal physiological pH in the range of 7.2-7.6, and the abnormal conditions are abnormal pH in the range of 5.5-7.2, 6-7, or 6.2-6.8. The assay solution for assaying under normal physiological conditions has normal physiological pH and 50 mM bicarbonate ion. The assay solution for assaying under abnormal conditions has abnormal pH and 50 mM bicarbonate ion. Since the pKa of bicarbonate ion is about 6.4, bicarbonate ion can support binding between the mutant polypeptide and its binding partner at abnormal pH of pH 6.0-6.4, e.g. pH 6.0 or 6.2.

[0154] In yet another embodiment, the normal physiological condition is a normal physiological pH in the range of 7.2-7.6, and the abnormal condition is an abnormal pH in the range of 5.5-7.2, 6-7, or 6.2-6.8. The assay solution for the assay under normal physiological conditions has a normal physiological pH and 80 μM citrate ion. The assay solution for the assay under abnormal conditions has an abnormal pH and 80 μM citrate ion. Since the citrate ion has a pKa of 6.4, the citrate ion can effectively support the binding between the mutant polypeptide and the binding partner in the assay solution under abnormal conditions of pH 6.0-6.4. Therefore, more candidate conditionally active polypeptides having higher binding activity under conditions of pH 6.0-6.4 and lower activity under pH conditions of 7.2-7.8 can be identified. Other ions, including acetate, histidine, bicarbonate, HATP and HADP function similarly, and assay solutions containing such ions allow for the effective screening of mutant polypeptides that have higher binding activity at a pH around the ion's pKa and lower binding activity at a pH different from the ion's pKa (e.g., normal physiological pH).

[0155] In yet another embodiment, the normal physiological conditions are normal physiological temperature of 37° C. and the abnormal conditions are abnormal temperature of 38-39° C. (temperatures in some tumor microenvironments). The assay solution for assaying under normal physiological conditions has normal physiological temperature and 20 mM bicarbonate. The assay solution for assaying under abnormal conditions has abnormal temperature and 20 mM bicarbonate.

[0156] In yet another embodiment, the normal physiological condition is a particular concentration of an electrolyte in normal human serum, and the abnormal condition is a concentration of the same electrolyte at a different abnormal concentration that may exist at a different location in the animal or human, or that may be caused by an animal or human condition that alters the normal physiological electrolyte concentration in human serum.

[0157] The binding between the variant polypeptide and / or its binding partner can also be influenced in a number of other ways. Typically, this can be influenced by including one or more additional components in the assay solution. These additional components can be designed to interact with either the variant polypeptide, the binding partner, or both. In addition, these additional components can affect binding using a combination of two or more interactions as well as a combination of two or more types of interactions.

[0158] In one embodiment, the binding interaction of interest is between an antibody and an antigen. In this embodiment, one or more additional components may be included in the assay solution to affect the antibody, the antigen, or both. In this manner, the desired binding interaction may be enhanced.

[0159] In addition to ions that may form ionic bonds with a mutant polypeptide and / or its binding partner to aid in binding between the mutant polypeptide and its binding partner, the present invention also includes other components that may be utilized to aid in binding between a mutant polypeptide and its binding partner. In one embodiment, molecules that may form hydrogen bonds with a mutant polypeptide and / or its binding partner may be utilized. In another embodiment, molecules capable of hydrophobic interactions with a mutant polypeptide and / or its binding partner may be used. In yet another embodiment, molecules capable of van der Waals interactions with a mutant polypeptide and / or its binding partner are contemplated.

[0160] "Hydrogen bond" refers to a relatively weak, non-covalent interaction between hydrogen covalently bonded to an electronegative atom such as carbon, nitrogen, oxygen, sulfur, chlorine, or fluorine (hydrogen bond donor) and the unshared pair of electrons of an electron-donating atom such as nitrogen, oxygen, sulfur, chlorine, or fluorine (hydrogen bond acceptor).

[0161] Moieties capable of forming hydrogen bonds with the variant polypeptide and / or its binding partner include organic molecules with polar bonds as well as inorganic molecules. The variant polypeptide and / or the binding partner of the variant polypeptide typically contain amino acids capable of forming hydrogen bonds. Suitable amino acids have side chains with polar groups capable of forming hydrogen bonds. Non-limiting examples of suitable amino acids include glutamine (Gln), glutamic acid (Glu), arginine (Arg), asparagine (Asn), aspartic acid (Asp), lysine (Lys), histidine (His), serine (Ser), threonine (Thr), tyrosine (Tyr), cysteine ​​(Cys), methionine (Met), and tryptophan (Trp).

[0162] These amino acids can function as both hydrogen donors and hydrogen acceptors, for example, the oxygen atom of an -OH group, as can be found in Ser, Thr, and Tyr, the oxygen atom of a -C=O group, as can be found in Glu and Asp, the sulfur atom of an -SH group or -SC-, as can be found in Cys and Met, the -NH group, as can be found in Lys and Arg, 3 + Nitrogen atoms of groups, as well as the nitrogen atoms of -NH- groups such as may be found in Trp, His, and Arg, can all function as hydrogen acceptors. Also, groups in this list that contain hydrogen atoms (e.g., -OH, -SH, NH 3 + and -NH-) can also function as hydrogen donors.

[0163] In some embodiments, the backbone of the variant polypeptide and / or its binding partner may also participate in the formation of one or more hydrogen bonds. For example, the backbone may have a repeating structure of -(C=O)-NH-, as in a peptide bond. The oxygen and nitrogen atoms of this structure may act as hydrogen acceptors, while the hydrogen atoms may participate in hydrogen bonds.

[0164] Inorganic compounds having at least one polar bond involving a hydrogen or oxygen atom that can be used for hydrogen bonding include, for example, H 2 O, NH 3 , H2 O 2 Examples of suitable hydrogen bonds include hydrazines, carbonates, sulfates, and phosphates. Alcohols, phenols, thiols, aliphatic amines, amides, epoxides, carboxylic acids, organic compounds such as ketones, aldehydes, ethers, esters, organic chlorides, and organic fluorines. Compounds capable of forming hydrogen bonds are well known in the chemical literature, for example, those discussed in "The Nature of the Chemical Bond," Linus Pauling, Cornell University Press, 1940, pages 284-334.

[0165] In some embodiments, alcohols may include methanol, ethanol, propanol, isopropanol, butanol, pentanol, 1-hexanol, 2-octanol, l-decanol, cyclohexanol, and higher alcohols; diols, such as ethylene glycol, propylene glycol, glycerol, diethylene glycol, and polyalkylene glycols. Suitable phenols include hydroquinone, resorcinol, catechol, phenol, o-, m-, and p-cresol, thymol, α- and β-naphthol, pyrogallol, guaiacol, and phloroglucinol. Suitable thiols include methanethiol, ethanethiol, 1-propanethiol, 2-propanethiol, butanethiol, tert-butylmercaptan, pentanethiols, hexanethiol, thiophenol, dimercaptosuccinic acid, 2-mercaptoethanol, and 2-mercaptoindole. Suitable amines include methylamine, ethylamine, propylamine, isopropylamine, aniline, dimethylamine and methylethylamine, trimethylamine, aziridine, piperidine, N-methylpiperidine, benzidine, cyclohexylamine, ethylenediamine, hexamethylenediamine, o-, m-, and p-toluidine and N-phenylpiperidine.Suitable amides include ethanamide, N,N-dimethylacetamide, N,N-dimethylformamide, N,N-dimethylmethoxyacetamide, and N-methyl-Np-cyanoethylformamide.Epoxides include ethylene oxide, propylene oxide, tert-butyl hydroperoxide, styrene oxide, epoxide glycidol, cyclohexene oxide, di-tert-butyl peroxide, cumene hydroperoxide or ethylbenzene hydroperoxide, isobutylene oxide, and 1,2-epoxyoctane.Examples of carboxylic acids include terephthalic acid, isophthalic acid, phthalic acid, salicylic acid, benzoic acid, acetic acid, lauric acid, adipic acid, lactic acid, citric acid, acrylic acid, glycine, hexahydrobenzoic acid, o-, m-, and p-toluic acid, nicotinic acid, isonicotinic acid, and para-aminobenzoic acid. Examples of ketones include acetone, 3-propanone, butanone, pentanone, methyl ethyl ketone, diisobutyl ketone, ethyl butyl ketone, methyl isobutyl ketone, methyl tert-butyl ketone, cyclohexanone, acetone, methyl ethyl ketone, methyl propyl ketone, methyl butyl ketone, methyl amyl ketone, methyl hexyl ketone, diethyl ketone, ethyl butyl ketone, dipropyl ketone, diisobutyl ketone, diacetone alcohol, phorone, isophorone, cyclohexanone, methylcyclohexanone, and acetophenone. Aldehydes include formaldehyde, acetaldehyde, propionaldehyde, butyraldehyde, benzaldehyde, cinnamaldehyde, isobutyraldehyde, valeraldehyde, octaldehyde, benzaldehyde, cinnamaldehyde, cyclohexanone, salicylaldehyde, and furfural.Esters include ethyl acetate, methyl acetate, ethyl formate, butyl acetate, ethyl lactate, ethyl butyrate, propyl acetate, ethyl formate, propyl formate, butyl formate, amyl formate, methyl acetate, ethyl acetate, propyl acetate, butyl acetate, amyl acetate, methyl isoamyl acetate, methoxybutyl acetate, hexyl acetate, cyclohexyl acetate, benzyl acetate, methyl propionate, ethyl propionate, butyl propionate, amyl propionate, methyl butyrate, ethyl butyrate, butyl butyrate, amyl butyrate, methyl acetoacetate, and ethyl acetoacetate. Ethers that may be used in the present invention include dimethyl ether, methyl ethyl ether, diethyl ether, methyl propyl ether, and dimethoxyethane. Ethers may also be cyclic, such as ethylene oxide, tetrahydrofuran, and dioxane.

[0166] The organic chlorides include chloroform, pentachloroethane, dichloromethane, trichloromethane, carbon tetrachloride, tetrachloromethane, tetrachloroethane, pentachloroethane, trichloroethylene, tetrachloroethylene, and ethylene dichloride.The organic fluorines can include fluoromethane, difluoromethane, trifluoromethane, trifluoroethane, tetrafluoroethane, pentafluoroethane, difluoropropane, trifluoropropane, tetrafluoropropane, pentafluoropropane, hexafluoropropane, and heptafluoropropane.

[0167] Hydrogen bonds can be classified as strong, medium, or weak, depending on the strength of the bond (Jeffrey, George A.; An introduction to hydrogen bonding, Oxford University Press, 1997). Strong hydrogen bonds have a donor-acceptor distance of 2.2-2.5 Å and an energy range of 14-40 kcal / mol. Medium hydrogen bonds have a donor-acceptor distance of 2.5-3.2 Å and an energy range of 4-15 kcal / mol. Weak hydrogen bonds have a donor-acceptor distance of 3.2-4.0 Å and an energy range of <4 kcal / mol. Some examples of hydrogen bonds, along with their energy levels, are FH···:F (38.6 kcal / mol), OH···:N (6.9 kcal / mol), OH···:O (5.0 kcal / mol), NH···:N (3.1 kcal / mol) and NH···:O (1.9 kcal / mol). For more information, see Perrin et al. "Strong" hydrogen bonds in chemistry and biology, Annual Review of Physical Chemistry, vol. 48, pages 511-544, 1997; Guthrie, "Short strong hydrogen bonds: can they explain enzymic catalysis?" Chemistry & Biology March 1996, 3:163-170.

[0168] In some embodiments, the components used in the present invention can form strong hydrogen bonds with the variant polypeptide and / or its binding partner. These components tend to have atoms with high electronegativity. The atoms known to have the highest electronegativity are in the order F>O>Cl>N. Therefore, the present invention preferably uses organic compounds containing fluorine, hydroxyl groups or carbonyl groups in forming hydrogen bonds. In one embodiment, organic fluorines may be used in the present invention to form strong hydrogen bonds.

[0169] In another embodiment, moieties capable of hydrophobic interaction with the mutant polypeptide and / or its binding partner are utilized. Such moieties include organic compounds with hydrophobic groups.

[0170] "Hydrophobic interaction" refers to a reversible attractive interaction between a hydrophobic compound or a hydrophobic region of a compound and another hydrophobic compound or a hydrophobic region of another compound. This type of interaction is described in "Hydrophobic Interactions," A. Ben-Nairn (1980), Plenum Press, New York.

[0171] Hydrophobic materials, due to their non-polar nature, experience the repulsive force of water molecules. When relatively non-polar molecules or groups in an aqueous solution associate with other non-polar molecules or groups rather than with water, this is called "hydrophobic interactions."

[0172] The variant polypeptides and their binding partners typically contain amino acids that have hydrophobic interaction capacity. These amino acids can typically be characterized by having at least one side chain with a non-polar group that has hydrophobic interaction capacity. Hydrophobic amino acids include, for example, alanine (Ala), isoleucine (Ile), leucine (Leu), phenylalanine (Phe), valine (Val), proline (Pro), glycine (Gly), and to a lesser extent methionine (Met), and tryptophan (Trp).

[0173] Components capable of hydrophobic interaction with the variant polypeptide and / or its binding partner include organic compounds that are hydrophobic molecules or molecules containing at least one hydrophobic moiety. In some embodiments, these hydrophobic components can be hydrocarbons selected from aromatic hydrocarbons, substituted aromatic hydrocarbons, polycyclic aromatic hydrocarbons, aromatic or non-aromatic heterocycles, cycloalkanes, alkanes, alkenes, and alkynes. Hydrophobic groups can include aromatic groups, alkyl, cycloalkyl, alkenyl, and alkynyl groups. The terms "alkyl", "alkenyl" and "alkynyl" as used herein refer to unsaturated aliphatic groups having 1-30 carbon atoms, including straight chain alkenyl / alkynyl groups, branched chain alkenyl / alkynyl groups, cycloalkenyl (alicyclic) groups, alkyl substituted cycloalkyl groups, and cycloalkyl substituted alkenyl / alkynyl groups. Such hydrocarbon moieties may also be substituted on one or more carbon atoms.

[0174] It can be understood that the strength of hydrophobic interactions is based on the amount of available "hydrophobes" that can interact with each other. Thus, hydrophobic interactions can be adjusted, for example, by increasing the amount of hydrophobic moieties in the molecule involved in the hydrophobic interaction and / or the nature of the "hydrophobicity". For example, a hydrophobic moiety (which in its original form may comprise a hydrocarbon chain) can be modified to increase its hydrophobicity (its ability to increase the strength of the hydrophobic interactions in which it participates) by adding a hydrophobic side chain to one of the carbons of its carbon backbone. In a preferred embodiment, this can include the addition of various polycyclic compounds, including, for example, various steroid compounds and / or their derivatives, such as sterol-based compounds, more particularly cholesterol. In general, the side chains can be linear, aromatic, aliphatic, cyclic, polycyclic, or any other various types of hydrophobic side chains as contemplated by those skilled in the art.

[0175] The types of moieties capable of van der Waals interactions with the variant polypeptide and / or its binding partner are usually, but not necessarily, compounds that have polar moieties. As used herein, "van der Waals interactions" refers to the attractive forces between atoms, moieties, molecules, and surfaces that arise due to the interrelationship of the fluctuating polarities of adjacent atoms, moieties, molecules as a result of dipole-dipole interactions and / or quantum dynamics.

[0176] Van der Waals interactions in the present invention are attractive forces between mutant polypeptides or binding partners and components. Van der Waals interactions can arise from three sources. First, some molecules / moieties can be permanent electric dipoles, even though they are electrically neutral. Due to fixed distortions of electronic charge distribution in the structure of some molecules / moieties, one side of the molecule / moiety is always somewhat positive and the other side somewhat negative. The tendency of such permanent dipoles to align with each other results in a net attractive force. This is the interaction between two permanent dipoles (Keesom force).

[0177] Second, the presence of a molecule that is a permanent dipole can temporarily distort the electronic charges of other adjacent polar or non-polar molecules, thereby inducing further polarization. An additional force of attraction arises when a permanent dipole interacts with an adjacent induced dipole. This is the interaction between a permanent dipole and a corresponding induced dipole and can be referred to as a Debye force. Third, even if the molecule involved is not a permanent dipole (e.g., the organic liquid benzene), there is still an attractive force between the molecules due to two instantly induced dipoles in the molecule. This is the interaction between two instantly induced dipoles and can be referred to as a London dispersion force.

[0178] There are many amino acids in the variant polypeptides and / or binding partners that have van der Waals interaction capabilities. These amino acids may have polar side chains, including glutamine (Gln), asparagine (Asn), histidine (His), serine (Ser), threonine (Thr), tyrosine (Tyr), cysteine ​​(Cys), methionine (Met), tryptophan (Trp). These amino acids may also have side chains with non-polar groups, including alanine (Ala), isoleucine (Ile), leucine (Leu), phenylalanine (Phe), valine (Val), proline (Pro), and glycine (Gly).

[0179] Components capable of van der Waals interactions with the variant polypeptide and / or its binding partner include polar or non-polar inorganic compounds that are soluble in the assay solution. The assay solution is generally an aqueous solution, and therefore these polar or non-polar inorganic compounds are preferably soluble in water. Preferred materials for van der Waals interactions are polar, such that they have the ability to interact with dipoles. For example, AlF 3 has polar Al-F bonds and is soluble in water (approximately 0.67 g / 100 ml water at 20°C). 2 has a polar Hg-Cl bond and is soluble in water at 7.4 g / 100 ml at 20°C. 2 has a polar Pr-Cl bond and is soluble in water at about 1 g / 100 ml at 20°C.

[0180] Suitable polar compounds capable of van der Waals interactions include alcohols, thiols, ketones, amines, amides, esters, ethers, and aldehydes. Suitable examples of these compounds are described above in relation to hydrogen bonding. Suitable non-polar compounds capable of van der Waals interactions include aromatic hydrocarbons, substituted aromatic hydrocarbons, polycyclic aromatic hydrocarbons, aromatic or non-aromatic heterocycles, cycloalkanes, alkanes, alkenes, and alkynes.

[0181] Hydrogen bonding components, hydrophobic components, and van der Waals components can be utilized to affect binding between a variant polypeptide and its binding partner in a number of ways. In one embodiment, crosslinks may be formed between a variant polypeptide and its binding partner by hydrogen bonding, hydrophobic interactions, and / or van der Waals interactions. Such crosslinks may bring the variant polypeptide and the binding partner into close proximity to one another to facilitate binding, and / or may position the variant polypeptide and / or the binding partner relative to one another to facilitate binding.

[0182] In another embodiment, hydrogen bonds and / or hydrophobic interactions may increase the likelihood that a mutant polypeptide will bind to its binding partner, for example, by causing the polypeptide and binding partner to assemble or associate with each other in a manner that increases the likelihood of binding. Thus, one or more of these interactions may be used alone or in combination to cause the mutant polypeptide and binding partner to assemble closer to each other or to position the mutant polypeptide and binding partner in a manner that promotes binding, for example, by drawing the binding sites closer to each other or by positioning the non-binding portions of the molecule away from each other, thereby positioning the binding sites closer to each other.

[0183] In yet another embodiment, hydrogen bonding and / or hydrophobic interactions may affect the conformation of the mutant polypeptide and / or its binding partner, resulting in a conformation that is more conducive to binding of the mutant polypeptide to its binding partner. Specifically, binding or interaction with one or more of the amino acids of the mutant polypeptide and / or binding partner may result in one or more conformational changes in the mutant polypeptide or binding partner that are favorable to the mutant polypeptide / binding partner binding reaction.

[0184] The present invention performs two pairs of assays, one that seeks a decrease in activity of the mutant polypeptide in an assay under normal physiological conditions compared to the parent polypeptide from which the mutant polypeptide was derived in normal physiological conditions, and a second assay that seeks an increase in activity of the mutant polypeptide in an assay under abnormal conditions compared to the parent polypeptide from which the mutant polypeptide was derived in abnormal conditions. The examples described in WO2017 / 078839 illustrate the selection of conditionally active polypeptides that are more active at the abnormal pH where activity is desired than at normal physiological pH.

[0185] In one embodiment, the mutant polypeptide is subjected to an assay under normal physiological conditions and an assay under abnormal conditions, and a conditionally active polypeptide is selected from a mutant polypeptide having an increased activity in an assay under abnormal conditions compared to the same activity of the mutant polypeptide in an assay under normal physiological conditions.

[0186] The conditions used in the assay pairs of the invention may be selected from temperature, pH, osmolality, osmolality, oxidative stress, electrolyte concentration and the concentration of any other components of the assay solution or medium. Thus, a particular component of the assay medium may be used at substantially the same concentration in both pairs of assays. In such cases, the component is typically present for the purpose of mimicking a particular environment in a human or animal, such as serum, a tumor microenvironment, a synovial fluid environment, a neurological environment, or any other environment that may be encountered at the point of administration, through which an administered treatment may pass, or at the point of treatment. An important aspect of the selection of one or more components that mimic these environments is that it may improve the results of the selection process performed with the assay pair. For example, mimicking a particular environment allows the selection process to evaluate different effects of certain components of that environment on the mutant polypeptide. A particular environmental component may, for example, alter or bind to the mutant polypeptide, inhibit the activity of the mutant polypeptide, inactivate the mutant polypeptide, etc.

[0187] In some embodiments, one or more components of the assay solution are preferably small molecules or ions, such as disulfide, hydrogen sulfide, histidine, histamine, citrate, bicarbonate, lactate, and acetate. In one embodiment, the small molecule or ion components are preferably present in the assay solution at a concentration of about 100 μm to about 100 mM, or more preferably about 0.5 to about 50 mM, or about 1 to about 10 mM.

[0188] The concentration of a component in the assay solution may be the same or substantially the same as the concentration of the same component typically found in a naturally occurring bodily fluid of a mammal, such as a human. This may be referred to as the normal physiological concentration of the component in the bodily fluid. In other embodiments, the concentration of a particular component in the assay solution may be lower or higher than the concentration of the same component typically found in a naturally occurring bodily fluid of a mammal, such as a human.

[0189] In another embodiment, the components may be present at substantially different concentrations in each of the assay pairs. In such cases, the presence, absence or concentration of the components becomes the condition that is assayed, since it is the concentration of the components that is the condition that distinguishes between the assay solution for the assay under normal physiological conditions and the assay solution for the assay under abnormal conditions. Thus, the conditionally active polypeptides produced by this embodiment of the method of the invention may be selected for an activity that is at least partially dependent on the concentration of the components.

[0190] In some embodiments, a component may be present in one pair of assay solutions but completely absent from the other pair of assay solutions. For example, the lactate concentration in the abnormal condition assay solution may be set to a level that mimics the lactate concentration in the tumor microenvironment. Lactate may be absent from the normal physiological condition assay solution pair.

[0191] In one embodiment, the normal physiological condition is a first lactate concentration representative of normal physiological conditions and the abnormal condition is a second lactate concentration representative of abnormal conditions present at a particular location in the body.

[0192] In another example, glucose may be absent in the abnormal condition assay solution to mimic the absence of glucose as may be found in a tumor microenvironment, while in the pair of normal physiological condition assay solutions glucose may be set to a level that mimics plasma glucose concentrations. This feature may be used to preferentially deliver a conditionally active polypeptide to a location or environment that is inactive or minimally active during transport, and activate the conditionally active polypeptide upon reaching an environment where a concentration of a component in the abnormal condition assay solution is present.

[0193] For example, the tumor microenvironment typically has both low glucose and high lactate concentrations compared to human serum. The normal physiological concentration of glucose ranges from about 2.5 mM to about 10 mM in serum. On the other hand, in the tumor microenvironment, the glucose concentration is typically very low, ranging from 0.05 mM to 0.5 mM. In one embodiment, the assay solution for assaying under normal physiological conditions has a glucose concentration ranging from about 2.5 mM to about 10 mM, and the assay solution for assaying under abnormal conditions has a glucose concentration ranging from about 0.05 mM to about 0.5 mM. The conditionally active polypeptide thus produced has higher activity in a low glucose environment (in the tumor microenvironment) than in a high glucose environment (in normal tissue or blood). The conditionally active polypeptide is functional in the tumor microenvironment, but may have low activity while passing through the bloodstream.

[0194] Normal physiological concentrations of lactate in serum range from about 1 mM to about 2 mM. On the other hand, in tumor microenvironments, lactate concentrations are typically in the range of 10 mM to 20 mM. In one embodiment, assay solutions for assays under normal physiological conditions have lactate concentrations in the range of about 1 mM to about 2 mM, and assay solutions for assays under abnormal conditions have lactate concentrations in the range of about 10 mM to about 20 mM. The conditionally active polypeptide thus produced has higher activity in a high lactate environment (in the tumor microenvironment) than in a low lactate environment (in normal tissue or blood). Thus, the conditionally active polypeptide is functional in the tumor microenvironment, but may have low activity while passing through the bloodstream.

[0195] Similarly, it is known that lactate concentrations are higher than normal (abnormal) in muscle pain. Thus, when searching for mutant polypeptides that may be active in a muscle pain environment, the abnormal condition assay pair can be performed in the presence of higher lactate concentrations to mimic the muscle pain environment, while the normal physiological condition assay pair can be performed at lower lactate concentrations or in the absence of lactate. In this way, mutant polypeptides can be selected that have improved activity with increasing lactate concentrations in a muscle pain environment. Such conditionally active polypeptides can be useful, for example, as anti-inflammatory agents.

[0196] In another embodiment, two or more components may be used in both pairs of assay solutions. In this type of assay, conditionally active polypeptides may be selected using both features of the two types of assays described above. Alternatively, two or more components may be used to increase the selectivity of conditionally active polypeptides. For example, returning to the tumor microenvironment, the abnormal condition assay pair may be performed in an assay medium that includes both high lactate and low glucose concentrations, while the corresponding normal physiological condition assay pair may be performed in an assay medium that includes both relatively low lactate and relatively high glucose concentrations.

[0197] The present invention contemplates that each component selected from inorganic compounds, ions, and organic molecules may be used alone or in combination to select conditionally active polypeptides that are more active at a given concentration of the component compared to a different concentration of the same component.

[0198] Assays that rely on differential concentrations of one or more metabolites as conditions that distinguish between a normal environment (normal physiological conditions) and an abnormal environment (abnormal conditions) can be particularly suitable for selecting conditionally active polypeptides that are more active in the tumor microenvironment than in plasma, because the tumor microenvironment typically has many metabolites that have different concentrations compared to the concentrations of the same metabolites in plasma.

[0199] Kinoshita et al., “Absolute Concentrations of Metabolites in Human Brain Tumors Using In Vitro Proton Magnetic Resonance Spectroscopy,” NMR IN BIOMEDICINE, vol. 10, pp. 2-12, 1997, compared metabolites in normal brain and brain tumors. The group found that N-acetylaspartic acid has a concentration of 5000-6000 μM in normal brain, but this concentration is only 300-400 μM in glioblastoma, 1500-2000 μM in astrocytoma, and 600-1500 μM in anaplastic astrocytoma. Furthermore, inositol has a concentration of 1500-2000 μM in normal brain, but this concentration is 2500-4000 μM in glioblastoma, 2700-4500 μM in astrocytoma, and 3800-5800 μM in anaplastic astrocytoma. Phosphorylethanolamine has a concentration of 900-1200 μM in normal brain, but this concentration is 2000-2800 μM in glioblastoma, 1170-1370 μM in astrocytoma, and 1500-2500 μM in anaplastic astrocytoma. Glycine has a concentration of 600-1100 μM in normal brain, but this concentration is 4500-5500 μM in glioblastoma, 750-1100 μM in astrocytoma, and 1900-3500 μM in anaplastic astrocytoma. Alanine has a concentration of 700-1150 μM in normal brain, but this concentration is 2900-3600 μM in glioblastoma, 800-1200 μM in astrocytoma, and 300-700 μM in anaplastic astrocytoma. These metabolites may also have different concentrations in the blood, for example, N-acetylaspartic acid has a concentration of about 85000 μM in the blood; inositol has a concentration of about 21700 μM in the blood; glycine has a concentration of about 220-400 μM in the blood; and alanine has a concentration of about 220-300 μM in the blood.

[0200] Thus, these metabolites, including at least N-acetylaspartic acid, inositol, glycine, and alanine, may be used in different concentrations in the assay solution to select conditionally active polypeptides that are active in brain tumors but not in blood or normal brain tissue. For example, to select conditionally active polypeptides that are active in the tumor microenvironment of glioblastoma but not active or at least less active in blood or normal brain tissue, an assay solution with a concentration of 85000 μM N-acetylaspartic acid may be used in the assay pair under normal physiological conditions, and an assay solution with a concentration of 350 μM N-acetylaspartic acid may be used in the assay pair under abnormal conditions.

[0201] Mayers et al., "Elevated circulating branched chain amino acids are an early event in pancreatic adenocarcinoma development," Nature Medicine, vol. 20, pp. 1193-1198, 2014, investigated the concentrations of various different metabolites, including branched chain amino acids, in the pre-diagnostic plasma of pancreatic patients. They found that pancreatic tumor patients have several metabolites that are present at different concentrations in their bloodstream compared to the concentrations of the same metabolites in the blood of people without pancreatic cancer. Mayers et al. (supra) also found that pancreatic cancer patients have a significant elevation of branched chain amino acids in their plasma compared to normal subjects. Branched chain amino acids that are present at elevated concentrations include isoleucine, leucine, and valine (Table 1 in Mayers et al. (supra)). There are other metabolites shown in Figure 1 in Mayers et al. (supra) that are present at significantly different concentrations in the plasma of pancreatic cancer patients compared to normal healthy humans. These metabolites include at least acetylglycine, glycine, phenylalanine, tyrosine, 2-aminoadipic acid, taurodeoxycholate / taurochenodeoxycholate, aconitate, isocitrate, lactate, a-glycerophosphate, and urate. Therefore, based on the finding that certain metabolites are present at different concentrations in the plasma of pancreatic cancer patients and normal healthy patients, it can be predicted that the tumor microenvironment of pancreatic cancer will also have different concentrations of these metabolites than may be present in the pancreatic microenvironment of healthy patients.

[0202] Thus, in one embodiment, one or more of these metabolites may be used in an assay solution under normal physiological conditions in amounts that approximate the concentrations of these metabolites in plasma of a healthy individual (i.e., the normal physiological concentrations of those metabolites). For example, the known normal physiological concentrations in plasma of a healthy individual are about 1.60±0.31 mg / dL for isoleucine, about 1.91±0.34 mg / dL for leucine, and about 2.83±0.34 mg / dL for valine. An assay solution under normal physiological conditions may have normal physiological concentrations of one or more of these branched amino acids within these ranges. An assay solution under abnormal conditions may have a concentration of the same branched amino acid that is about 5 times, or about 10 times, or about 20 times, or about 50 times, or about 70 times, or about 100 times, or about 150 times, or about 200 times, or about 500 times higher than the normal physiological concentration of the corresponding branched amino acid in a healthy individual. This may reflect that the higher concentrations of these branched amino acids found in plasma by Mayers et al. (supra) arise from the tumor microenvironment and are diluted in the bloodstream, and therefore, based on the findings of Mayers et al. (supra), the concentrations of these branched amino acids may be expected to be significantly elevated in the pancreatic tumor microenvironment. Similarly, assays under abnormal conditions may reflect the concentrations of other metabolites in the blood of pancreatic cancer patients, even if the concentrations of certain metabolites are significantly lower in cancer patients compared to normal individuals. In this way, screening can mimic the real environment, thereby ensuring that the most active variants for the particular environment of interest are selected.

[0203] In some other embodiments, the assay solution for normal physiological conditions may contain one or more branched amino acids at concentrations that mimic the concentrations in the plasma of patients with pancreatic cancer to mimic the actual plasma environment of these patients. In such embodiments, the assay solution for abnormal conditions may have a concentration of the same branched amino acid that is about 2-fold, or about 3-fold, or about 4-fold, or about 5-fold, or about 7-fold, or about 8-fold, or about 10-fold, or about 15-fold, or about 20-fold, or about 50-fold higher than the concentration of the corresponding branched amino acid in the plasma of patients with pancreatic cancer to reflect the fact that these higher concentrations occur in the tumor microenvironment and that the concentrations in the bloodstream represent a dilution of the actual concentrations in the tumor microenvironment. Similarly, other metabolites may also have different concentrations in the assay solution for normal physiological conditions and abnormal conditions, which may reflect the actual differences expected from the data collected on the bloodstream. In some cases, a particular metabolite may be deficient in the bloodstream of a pancreatic patient, in which case a concentration reflective of the measured bloodstream concentration may be used to assay for normal physiological conditions, and a lower concentration may be used to assay for abnormal conditions to take into account the expectation that the metabolite would be consumed in the tumor microenvironment. Conditionally active polypeptides selected using such assay solutions may be more active in the pancreatic cancer microenvironment compared to in the plasma of pancreatic cancer patients.

[0204] In some embodiments, whole plasma of a pancreatic cancer patient may be used in the present invention. For example, in one embodiment, one or more components of plasma of a pancreatic cancer patient may be simulated in the assay solution for one or both of the assays under normal physiological conditions and abnormal conditions. In an exemplary embodiment, the assay solution under normal physiological conditions has a pH in the range of 7.2-7.6 and is spiked with 30 wt.% plasma of a pancreatic cancer patient, and the assay solution under abnormal conditions has a pH in the range of 6.2-6.8 and is spiked with 30 wt.% plasma of a pancreatic cancer patient. In this embodiment, the plasma of the pancreatic cancer patient is present both to (1) ensure that the conditionally active polypeptide is not activated in blood at pH 7.2-7.6, and (2) also ensure that the conditionally active polypeptide can be activated by pH 5.5-7.2, 6-7, or 6.2-6.8 in the tumor microenvironment, even in the presence of this metabolic product composition found in the blood of a pancreatic cancer patient. This allows the treatment to be tailored to the pancreatic cancer patient.

[0205] In another exemplary embodiment, the assay solution under normal physiological conditions has a pH in the range of 7.2 to 7.6 and is supplemented with 30 wt.% plasma from a pancreatic cancer patient, while the assay solution under abnormal conditions has a pH in the range of 5.5 to 7.2 or 6.2 to 6.8 and is not supplemented with any plasma from a pancreatic cancer patient.

[0206] In each of the several types of assays discussed above, the same components selected from inorganic compounds, ions, and organic molecules may be used. For example, in the case of lactate, lactate may be used at substantially the same concentration in both pairs of assay solutions under normal physiological conditions and abnormal conditions. The normal physiological conditions and abnormal conditions will in turn differ in one or more other aspects, such as temperature, pH, concentration of other components, etc. In different embodiments, lactate may be used as one of the factors that distinguish between normal physiological conditions and abnormal conditions, thereby reflecting that lactate is at a higher concentration in the abnormal tumor microenvironment compared to the normal physiological conditions (non-tumor microenvironment).

[0207] In some embodiments, two or more components are added to both the normal and abnormal conditions assay solutions at substantially the same concentration. For example, both citrate and bovine serum albumin (BSA) are added to these assay solutions. The citrate concentration in both assay solutions may be about 80 μM and the BSA concentration may be about 10-20%. More specifically, the assay solution for the assay pair under normal physiological conditions may have a pH in the range of 7.2-7.6, with citrate at a concentration of about 80 μM and BSA at a concentration of about 10-20%. The assay solution for the assay pair under abnormal conditions may have a pH in the range of 6.2-6.8, with citrate at a concentration of about 80 μM and BSA at a concentration of about 10-20%.

[0208] In one embodiment, serum may be added to both the normal and abnormal conditions assay solutions at substantially the same concentration. Since serum has a large number of inorganic compounds, ions, and organic molecules (including polypeptides), the assay solution may have a plurality and a large number of components selected from inorganic compounds, ions, and organic molecules that are present at substantially the same concentration between the two assay solutions. The assay solution may have 5-30 vol.%, or 7-25 vol.%, or 10-20 vol.%, or 10-15 vol.% serum. In some other embodiments, both the normal and abnormal conditions assay solutions are serum-free. The serum may be human serum, bovine serum, or serum from any other mammal. In some other embodiments, the assay solution is serum-free.

[0209] Assay solutions under normal and abnormal physiological conditions may have different pHs. The pH of such assay solutions can be adjusted by adjusting the CO in the buffer using bicarbonate. 2 and O 2 The level can be adjusted.

[0210] In some other embodiments, at least one of the two or more components is added at different concentrations to the assay solutions under normal and abnormal physiological conditions. For example, both lactate and bovine serum albumin (BSA) are added to the assay solutions. The lactate concentration may differ between the assay solutions under normal and abnormal physiological conditions, while BSA may have the same concentration in both assay solutions. Lactate may have a concentration in the range of 30-50 mg / dL in the assay solution under abnormal conditions and a concentration in the range of 8-15 mg / dL in the assay solution under normal physiological conditions. On the other hand, BSA has the same concentration in both assay solutions, such as about 10-20%. The conditionally active polypeptide thus selected by using these assay solutions is more active at high lactate concentrations of 30-50 mg / dL compared to low lactate concentrations of 8-15 mg / dL in the presence of BSA.

[0211] In some embodiments, the assay solution may be designed to select for conditionally active polypeptides whose activity depends on two or more conditions. In one exemplary embodiment, the conditionally active polypeptide may have activity that is both pH and lactate dependent. The assay solution for selecting such conditionally active polypeptides may be an assay solution with a pH of 7.2-7.6 and a lactate concentration in the range of 8-15 mg / dL for normal physiological conditions. The assay solution for abnormal conditions may be an assay solution with a pH of 6.2-6.8 and a lactate concentration in the range of 30-50 mg / dL. Optionally, the assay solutions for both normal and abnormal physiological conditions may also contain ions that aid in binding between the mutant polypeptide and its binding partner, thus increasing the number of hits for the candidate biologically active polypeptide.

[0212] In yet another exemplary embodiment, the conditionally active polypeptide may have activity that is dependent on pH, glucose, and lactate. The assay solution for selecting such conditionally active polypeptides may have an assay solution with a pH of 7.2-7.6, a glucose concentration in the range of 2.5-10 mM, and a lactate concentration in the range of 8-15 mg / dL for normal physiological conditions. The assay solution for abnormal conditions may have a pH of 6.2-6.8, a glucose concentration in the range of 0.05-0.5 mM, and a lactate concentration in the range of 30-50 mg / dL. Optionally, the assay solutions for both normal and abnormal physiological conditions may also contain ions that support binding between the mutant polypeptide and its binding partner, thus increasing the number of candidate biologically active polypeptides that bind to the binding partner at pH 6.2-6.8. A conditionally active polypeptide selected using such an assay solution is more active in an environment of pH 6.2-6.8, a glucose concentration of 0.05-0.5 mM, and a lactate concentration of 30-50 mg / dL than in an environment of pH 7.2-7.6, a glucose concentration of 2.5-10 mM, and a lactate concentration of 8-15 mg / dL.

[0213] The two or more components selected from inorganic compounds, ions, and organic molecules are for creating an abnormal condition assay solution that mimics the environment of the location / site (i.e., the target site) to which the selected conditionally active polypeptide is to be delivered. In some embodiments, at least three components in the target site environment may be added to the assay solution, or at least four components in the target site environment may be added to the assay solution, or at least five components in the target site environment may be added to the assay solution, or at least six components in the target site environment may be added to the assay solution.

[0214] In one embodiment, bodily fluid collected from a target site (where the conditionally active polypeptide may be more active) may be directly used as an assay solution for the abnormal condition assay. For example, synovial fluid may be collected from a subject, preferably a subject with a joint disease in need of treatment. The collected synovial fluid may be optionally diluted and used as an assay solution in an abnormal condition assay pair to select the conditionally active polypeptide. By using the collected synovial fluid, optionally diluted, as an assay solution for the abnormal condition assay and an assay solution that mimics human plasma for the normal physiological condition assay, the selected conditionally active polypeptide (e.g., TNF-α) may be more active in the joint than in other locations or organs. For example, a subject with an inflamed joint (such as arthritis) may be treated with TNF-α. However, TNF-α typically has severe side effects that damage other tissues and organs. Conditionally active TNF-α, which is highly active in synovial fluid but not or less active in the blood, may deliver the activity of TNF-α to the joints while reducing or potentially eliminating the side effects of TNF-α on other parts of the body.

[0215] The development of a conditionally active polypeptide with activity dependent on multiple conditions will result in improved selectivity of the conditionally active polypeptide to target sites in the subject's body. Ideally, the conditionally active polypeptide is not active, or at least is significantly less active, in other locations where only some of the conditions are present. In one embodiment, a conditionally active polypeptide that is active at pH 6.2-6.8, glucose concentration 0.05-0.5 mM, and lactate concentration 30-50 mg / dL can be delivered specifically to the tumor microenvironment, since all of these conditions are present in the tumor microenvironment. Other tissues or organs may only have one or two of these conditions, but not all three, and therefore are insufficient to fully activate the conditionally active polypeptide in other tissues or organs. For example, post-exercise muscle may have a low pH in the range of 6.2-6.8. However, it may not have the alternative assay conditions. Thus, the conditionally active polypeptide is not active, or at least is less active, in post-exercise muscle.

[0216] In some embodiments, a step may be performed to confirm that the activity of the conditionally active polypeptide is indeed dependent on the conditions used to select the conditionally active polypeptide. For example, a conditionally active polypeptide may be selected that is dependent on three conditions: pH 6.2-6.8, glucose concentration 0.05-0.5 mM, and lactate concentration 30-50 mg / dL. The selected conditionally active polypeptide may then be tested individually under each of these three conditions, and in environments that include pairs of the three conditions, to confirm that the conditionally active polypeptide is not active or has low activity under these test conditions or environments.

[0217] In some embodiments, certain components of serum are intentionally minimized or excluded from the assay medium. For example, when screening for antibodies, components of serum that bind or adsorb the antibodies can be minimized or excluded from the assay medium. Such bound antibodies can generate false positives, thereby including binding mutant antibodies that are not conditionally active, but rather simply bind to components present in serum under a variety of different conditions. Thus, by using careful selection of assay components such that components that can potentially bind to the variants in the assay are minimized or excluded, the number of non-functional variants that can be falsely identified as positive for conditional activity due to binding to components in the assay other than the desired binding partner can be reduced. For example, in some embodiments screening for variant polypeptides that tend to bind to components in human serum, BSA can be used in the assay solution to reduce or eliminate the possibility of false positives caused by variant polypeptides binding to components in human serum. Other similar substitutions can also be made in the detailed examples to achieve the same goal.

[0218] In some embodiments, the assay conditions mimic the environment near the cell membrane, such as inside the cell membrane, on the cell membrane, or outside the cell membrane, or the joint environment. Some factors that may affect the binding activity during screening in the cell membrane environment include receptor expression, internalization, antibody drug conjugate (ADC) potency, etc.

[0219] The format of the assay can be any suitable assay known to those skilled in the art. Examples include ELISA, enzyme activity assays, in vitro (such as organ) real tissue screening, tissue slides, whole animals, cell lines and the use of 3D systems. For example, suitable cell-based assays are described in WO2013 / 040445, tissue-based assays are described in US7,993,271, whole animal-based screening methods are described in US2010 / 0263599, and 3D system-based screening methods are described in US2011 / 0143960.

[0220] In some embodiments, the evolution process may generate variant polypeptides that may simultaneously possess other desired properties in addition to the conditionally active properties discussed above. Suitable other desired properties that may be evolved include binding activity, expression, humanization, etc. Thus, the present invention may be used to generate conditionally active polypeptides that also have improved at least one or more of these other desired properties.

[0221] In some embodiments, the selected conditionally active polypeptides can be further mutated, for example in a second evolution step, using one of the mutagenesis techniques disclosed herein, to improve another property of the selected conditionally active polypeptide, such as binding activity, expression, humanization, etc. After this second evolution step, the mutant polypeptides can be screened for both conditional activity and the improved property.

[0222] In some embodiments, after evolving the parent polypeptide to generate mutant polypeptides, a first conditionally active polypeptide is selected that exhibits both an increase in the first activity in an assay under abnormal conditions compared to the first activity under normal physiological conditions. The first conditionally active polypeptide can then be subjected to one or more additional evolution, expression and selection steps to select at least a second conditionally active polypeptide that exhibits either (1) an increase in the second activity in an assay under abnormal conditions compared to the second activity in an assay under normal physiological conditions, or (2) a greater ratio of the first activity under abnormal conditions to the first activity under normal physiological conditions compared to the first conditionally active polypeptide and / or the parent polypeptide. The second conditionally active polypeptide can have both a higher first activity and a higher second activity under abnormal conditions compared to the respective activities under normal physiological conditions, and both a lower first activity and a lower second activity under normal physiological conditions compared to the parent polypeptide.

[0223] In certain embodiments, the present invention aims to generate conditionally active polypeptides that have a greater ratio of activity under abnormal conditions to activity under normal physiological conditions (e.g., greater selectivity between abnormal and normal physiological conditions). The ratio of activity under abnormal conditions to activity under normal physiological conditions, i.e., selectivity, can be at least about 2:1, or at least about 3:1, or at least about 4:1, or at least about 5:1, or at least about 6:1, or at least about 7:1, or at least about 8:1, or at least about 9:1, or at least about 10:1, or at least about 11:1, or at least about 12:1, or at least about 13:1, or at least about 14:1, or at least about 15:1, or at least about 16:1, or at least about 17:1, or at least about 18:1, or at least about 19:1, or at least about 20:1, or at least about 30:1, or at least about 40:1, or at least about 50:1, or at least about 60:1, or at least about 70:1, or at least about 80:1, or at least about 90:1, or at least about 100:1.

[0224] In one embodiment, the conditionally active polypeptide is an antibody, which may have a ratio of activity under abnormal conditions to activity under normal physiological conditions of at least about 5:1, or at least about 6:1, or at least about 7:1, or at least about 8:1, or at least about 9:1, or at least about 10:1, or at least about 15:1, or at least about 20:1, or at least about 40:1, or at least about 80:1. In one embodiment, the conditionally active polypeptide is used to target tumor sites, where the conditionally active polypeptide is active at the tumor site (in the tumor microenvironment) and is significantly less active or inactive at non-tumor sites (normal physiological conditions).

[0225] In one embodiment, the conditionally active polypeptide is an antibody intended to be conjugated with another agent, such as those disclosed elsewhere herein. The conditionally active antibody may have a higher ratio of activity under abnormal conditions to activity under normal physiological conditions. For example, the conditionally active antibody conjugated with another agent may have a ratio of activity under abnormal conditions to activity under normal physiological conditions of at least about 10:1, or at least about 11:1, or at least about 12:1, or at least about 13:1, or at least about 14:1, or at least about 15:1, or at least about 16:1, or at least about 17:1, or at least about 18:1, or at least about 19:1, or at least about 20:1. This may be particularly important when the conjugated agent is, for example, toxic or radioactive, since it is desirable to concentrate such conjugated agent at the disease or treatment site (where the abnormal condition exists).

[0226] H. Confirmation of the pI of the Conditionally Active Polypeptide In some embodiments, the pI of the selected conditionally active polypeptide is confirmed to be lower than the pI of the parent polypeptide using any of the techniques described above. For example, the pI of the conditionally active polypeptide may be at least 0.1, or at least 0.2, or at least 0.3, or at least 0.4, or at least 0.5, or at least 0.6, or at least 0.8, or at least 1.0, or at least 1.2, or at least 1.4, or at least 1.5, or at least 1.7, or at least 2.0, or at least 2.5, or at least 3.0, or at least 3.5, or at least 4.0, or at least 5.0 units lower than the pI of the parent polypeptide.

[0227] I. Conditionally Active Polypeptides In another aspect, the invention provides a conditionally active polypeptide having a pI lower than the pI of a parent polypeptide, the activity of the conditionally active polypeptide is increased under abnormal conditions that deviate from normal physiological conditions, as compared to the same activity of the same mutant polypeptide under corresponding normal physiological conditions, and in some cases, (a) the activity is increased under abnormal conditions that deviate from normal physiological conditions, compared to the same activity of the parent polypeptide under the same abnormal conditions; (b) the activity is decreased under normal physiological conditions compared to the same activity of the parent polypeptide under the same normal physiological conditions; or (c) A combination of (a) and (b) above.

[0228] Conditionally active polypeptides are reversibly or irreversibly inactivated under normal physiological conditions, but are active under abnormal conditions, hi some embodiments, these conditionally active polypeptides may have activity under abnormal conditions that is equal to or greater than the same activity of the parent polypeptide under normal physiological conditions.

[0229] Conditionally active polypeptides are particularly valuable for the development of therapeutic agents that are active for a limited period of time in the host. This is particularly valuable when a limited activity is required to achieve the desired treatment, but prolonging the action of the treatment would be detrimental to the host. Examples of beneficial applications include local or systemic treatment, as well as topical treatment. One advantage of conditionally active polypeptides is that higher doses can be used for therapeutic applications, potentially reducing adverse side effects. Inactivation under normal physiological conditions can be used to reduce adverse side effects.

[0230] Inactivation under normal physiological conditions can be determined by a combination of the dosage of the polypeptide and the rate of inactivation, which is particularly important for enzyme therapies that can cause substantial negative side effects in a relatively short period of time.

[0231] Conditionally active polypeptides may also be activated or inactivated time-reversibly or irreversibly, or may be activated or inactivated only when located in a particular microenvironment within the body, including a particular organ within the body. Exemplary microenvironments may include, but are not limited to, tumors, synovial fluid, and the microenvironments of the bladder or kidney.

[0232] In some embodiments, the conditionally active polypeptide is an antibody or antibody fragment against one or more target antigens described herein.

[0233] The abnormal condition and normal physiological condition can be selected from temperature, pH, osmolality, osmolality, oxidative stress, electrolyte concentration, and combinations of two or more of such conditions, as discussed above.In some embodiments, the condition is pH, and the conditionally active polypeptide has an activity that is pH-dependent.Specifically, the conditionally active polypeptide has increased activity at abnormal pH compared to that at normal physiological pH.

[0234] In one aspect, the invention relates to conditionally active polypeptides that have a pH-dependent activity in the presence of a species having a pKa within 0.5, 1, 1.5, 2, 2.5, 3 or 4 units of the pH at which activity is desired. In another aspect, the invention relates to conditionally active polypeptides that have a pH-dependent activity in the presence of a species having a pKa of about 4 to about 10, or about 4.5 to about 9.5, or about 5 to about 9, or about 5.5 to about 8, or about 6.0 to about 7.0.

[0235] Species present in the assay medium that have a large effect on the activity of a conditionally active polypeptide tend to be species that have at least two ionized states: an uncharged or low charged state and a charged or high charged state. Thus, the pKa of a species that has a consequence on the activity of a conditionally active polypeptide can be useful in determining the extent to which that species has a consequence on a particular activity of the polypeptide at a particular pH.

[0236] In another aspect, the invention relates to a conditionally active polypeptide having a pH-dependent activity in the presence of a species selected from histidine, histamine, hydrogenated adenosine diphosphate, hydrogenated adenosine triphosphate, citrate, bicarbonate, acetate, lactate, disulfide, hydrogen sulfide, ammonium, dihydrogen phosphate, and any combination thereof. In some embodiments, the pH-dependent conditionally active polypeptide has a higher activity at a second pH than at a first different pH, and both activities are measured in an assay in the presence of these species. To determine the pH-dependence of a conditionally active polypeptide, the same activity of the polypeptide is assayed at two different pH values ​​in the same assay medium.

[0237] The ratio of the activity at a second pH to the same activity at a first pH in the same assay medium is referred to as the selectivity of the pH-dependent conditionally active polypeptide. A pH-dependent conditionally active polypeptide has a selectivity of at least about 1.3, or at least about 1.5, or at least about 1.7, or at least about 2.0, or at least about 3.0, or at least about 4.0, or at least about 6.0, or at least about 8.0, or at least about 10.0, or at least about 20.0, or at least about 40.0, or at least about 60.0, or at least about 100.0.

[0238] It has often been observed that pH-dependent conditionally active polypeptides have an increased number (or percentage) of charged amino acid residues compared to the amino acid residues of the parent polypeptide from which the conditionally active polypeptide is derived. There are three positively charged amino acid residues: lysine, arginine and histidine; and two negatively charged amino acid residues: aspartic acid and glutamic acid. In some embodiments, these charged amino acid residues are present in excess in the pH-dependent conditionally active polypeptide compared to the parent polypeptide from which the pH-dependent conditionally active polypeptide is derived. As a result, the pH-dependent conditionally active polypeptide has an increased number of charged amino acid residues compared to the parent polypeptide, and is therefore more likely to interact with charged species in the assay medium. This in turn affects the activity of the conditionally active polypeptide.

[0239] It has also been observed that pH-dependent conditionally active polypeptides typically have different activities in the presence of different species in the assay medium. Species with at least two ionized states, an uncharged or low-charged state and a charged or high-charged state, can dissociate to a greater extent at a particular pH depending on their pKa values, thereby increasing the likelihood of interaction with charged amino acid residues present in the conditionally active polypeptide. This feature can be used to increase the selectivity and / or pH-dependent activity of the conditionally active polypeptide.

[0240] The nature of the charge on the conditionally active polypeptide may be one factor used to determine the species suitable for influencing the activity of the conditionally active polypeptide. In some embodiments, the conditionally active polypeptide may have more positively charged amino acid residues: lysine, arginine, and histidine compared to the parent polypeptide. Alternatively, the conditionally active polypeptide may have more negatively charged amino acid residues: aspartic acid and glutamic acid compared to the parent polypeptide. In this manner, the conditionally active polypeptide may be selected to have a desired level of interaction with a particular species present in the environment in which its activity is desired and / or to have a desired level of interaction with a particular species present in the environment in which reduced activity is desired.

[0241] The location of charged amino acid residues on a pH-dependent conditionally active polypeptide may also affect the activity of the conditionally active polypeptide, for example, the proximity of charged amino acid residues to the binding site of a conditionally active polypeptide may affect the binding activity of the polypeptide.

[0242] In some embodiments, interaction of a charged environmental species with the conditionally active polypeptide may block or impede activity of the pH-dependent conditionally active polypeptide, for example, a charged amino acid that interacts with a charged environmental species may exert an allosteric effect on the binding site of the conditionally active polypeptide.

[0243] In other embodiments, the interaction of the charged environmental species with the conditionally active polypeptide may result in the formation of salt bridges between different moieties on the polypeptide, particularly between charged and polar moieties. The formation of salt bridges is known to stabilize polypeptide structures (Donald, et al., "Salt Bridges: Geometrically Specific, Designable Interactions," Proteins, 79(3): 898-915, 2011; Hendsch, et al., "Do salt bridges stabilize proteins? A continuum electrostatic analysis," Protein Science, 3:211-226, 1994). Salt bridges can stabilize or fix protein structures that undergo constant small structural changes, usually referred to as "breathing" (Parak, "Proteins in action: the physics of structural fluctuations and conformational changes," Curr Opin Struct Biol., 13(5):552-557, 2003). Protein structural "breathing" is important for protein function and binding, because structural fluctuations may enable the protein to recognize and bind its partners efficiently (Karplus, et al., "Molecular dynamics and protein functions," PNAS, vol. 102, pp. 6679-6685, 2015). By forming salt bridges, the binding site on the conditionally active polypeptide, especially the binding pocket, may become less accessible to the partner. This is probably because the salt bridges directly prevent the partner from accessing the binding site or reduce the "breathing" of the protein structure. Even with salt bridges far from the binding site, the allosteric effect of the salt bridges may change the conformation of the binding site and inhibit binding. Thus, after the salt bridges stabilize (fix) the structure of the conditionally active polypeptide, the polypeptide may become less active in binding to its partner, resulting in reduced activity.

[0244] Hemoglobin is one of the polypeptides whose structure is stabilized by salt bridges. Structural and chemical studies have revealed that salt bridges in hemoglobin involve at least two pairs of chemical groups: the amino terminus and side chains of histidines β146 and α122, which have pKa values ​​close to pH 7. In deoxyhemoglobin, the terminal carboxylate group of β146 forms a salt bridge with a lysine residue in the α subunit of the other αβ dimer. This interaction fixes the side chain of histidine β146 in a position where it can participate in a salt bridge with the negatively charged aspartic acid 94 of the same chain, provided that the imidazole group of the histidine residue is protonated (Figure 1). At high pH, ​​the side chain of histidine β146 is not protonated and no salt bridge is formed. However, as the pH decreases, the side chain of histidine β146 becomes protonated and a salt bridge forms between histidine β146 and aspartic acid β94, stabilizing the quaternary structure of deoxyhemoglobin and leading to an increased propensity for oxygen release in actively metabolizing tissues (where the pH is lower). Hemoglobin exhibits a pH-dependent binding activity for oxygen, such that at low pH, the binding activity for oxygen decreases due to the formation of salt bridges. On the other hand, at high pH, ​​the binding activity for oxygen increases due to the absence of these salt bridges.

[0245] Similarly, ions such as bicarbonate ions can reduce the binding activity of a conditionally active polypeptide to its partner by forming salt bridges in the conditionally active polypeptide. For example, at a pH greater than the pKa of bicarbonate ion, bicarbonate ions become negatively charged. Negatively charged bicarbonate ions can form salt bridges between positively charged or polar moieties on the conditionally active polypeptide. These salt bridges prevent or reduce binding of the conditionally active polypeptide to its partner. At a pH lower than 6.4, bicarbonate ions are protonated and neutralized. Uncharged bicarbonate cannot form salt bridges and thus would not affect binding of the conditionally active polypeptide to its partner. In this scenario, the conditionally active polypeptide can have a higher binding activity with its partner at a pH less than 6.4, the pKa of bicarbonate, than at a higher pH greater than 6.4. In this example, the conditionally active polypeptide is conditionally active in the presence of bicarbonate ions, i.e., it exhibits pH-dependent activity.

[0246] In the absence of species such as bicarbonate in the assay medium, a conditionally active polypeptide may lose its conditional activity. This is likely due to the absence of salt bridges on the conditionally active polypeptide that stabilize (fix) the structure of the polypeptide. Thus, in the absence of bicarbonate, the binding partner may have similar access to the binding site on the conditionally active polypeptide at every pH, resulting in similar activity at every pH and eliminating conditional activity.

[0247] In other embodiments, interaction of a small molecule or ion with a conditionally active polypeptide may alter the structure of the polypeptide in a manner that alters its activity. For example, the structural change may improve the binding affinity of the conditionally active polypeptide by changing the position, steric hindrance, or binding energy for the binding site. In such cases, it may be desirable to select a small molecule or ion that binds to the conditionally active polypeptide at the pH where activity is desired.

[0248] Although salt bridges (ionic bonds) are the strongest and most common way that compounds and ions affect the activity of conditionally active polypeptides, it will be understood that other interactions between such compounds and ions and the conditionally active polypeptides may also contribute to stabilize or fix the structure of the conditionally active polypeptide. Such other interactions include hydrogen bonds, hydrophobic interactions, and van der Waals interactions.

[0249] In some embodiments, to select a suitable compound or ion, the conditionally active polypeptide is compared to the parent polypeptide from which it was evolved, and it is determined whether the conditionally active polypeptide has a higher proportion of negatively or positively charged amino acid residues. Compounds or ions with appropriate charges at the desired pH and normal physiological pH, respectively, can then be selected based on their size and pKa value to affect the activity of the conditionally active polypeptide. For example, if the conditionally active polypeptide has a higher proportion of positively charged amino acid residues than the parent polypeptide, a suitable small molecule or ion should typically be negatively charged at normal physiological pH and neutral at the desired pH to interact with the conditionally active polypeptide. On the other hand, if the conditionally active polypeptide has a higher proportion of negatively charged amino acid residues than the parent polypeptide, a suitable small molecule or ion should typically be positively charged at normal physiological pH and neutral at the desired pH to interact with the conditionally active polypeptide.

[0250] In other embodiments, the activity of the conditionally active polypeptide is controlled by the interaction of a small molecule or ion with a target polypeptide that is a binding partner of the conditionally active polypeptide. In this case, the same principles discussed above are equally applicable, except that the goal is to create an interaction between a small molecule or ion and a target polypeptide. The target polypeptide can be, for example, an antigen for a conditionally active antibody or a ligand for a conditionally active receptor.

[0251] Suitable small molecules or ions can be any inorganic or organic compounds or ions that transition from an uncharged or low-charged state at the pH where activity is desired to a charged or high-charged state at normal physiological pH. Thus, small molecules or ions should typically have a pKa between the pH where activity is desired and normal physiological pH. For example, bicarbonate has a pKa of 6.4. Thus, at pH 7.4, for example, negatively charged bicarbonate may bind to the charged amino acid residues of the conditionally active polypeptide, reducing activity. On the other hand, at a lower pH, such as pH 6.0, low-charged bicarbonate may not bind to the conditionally active polypeptide in the same amount, allowing for higher activity of the conditionally active polypeptide.

[0252] Disulfides have a pKa of 7.05. Thus, at normal physiological pH, such as pH 7.4, more negatively charged disulfides may bind to the positively charged amino acid residues of a conditionally active polypeptide, reducing its activity. On the other hand, at lower pH, such as pH 6.2-6.8, less charged hydrogen sulfide / disulfides do not bind to the conditionally active polypeptide at the same level, thus allowing for higher activity of the conditionally active polypeptide.

[0253] Small molecules or ions having a pKa between the pH at which activity is desired and normal physiological pH are preferred for use in the present invention. Preferred species are selected from disulfide, hydrogen sulfide, histidine, histamine, citrate, bicarbonate, acetate, and lactate. Each of these small molecules or ions has a pKa of 6.2 to 7.0. In addition, other small molecules such as tricine (pKa 8.05) and bicine (pKa 8.26) may also be used. Other suitable small molecules or ions can be found using the principles of the present application in textbooks such as CRC Handbook of Chemistry and Physics, 96th Edition, by CRC press, 2015 and Chemical Properties Handbook, McGraw-Hill Education, 1998.

[0254] The concentration of the small molecule or ion in the assay medium or environment is preferably at or near the physiological concentration of the small molecule or ion in the subject. For example, the physiological concentration of bicarbonate in human serum is in the range of 15-30 mM. Thus, the concentration of bicarbonate in the assay medium may be 10 mM-40 mM, or 15 mM-30 mM, or 20 mM-25 mM, or about 20 mM. The concentration of disulfide in the assay medium may be 3-500 nM, or 5-200 nM, or 10-100 nM, or 10-50 nM.

[0255] In the present invention, the conditionally active polypeptide is selected and utilized at a concentration such that the normal physiological concentration of the particular species in the environment can have a significant effect on the activity of the conditionally active polypeptide in the pH range of interest. Thus, in many therapeutic treatments, it would be advantageous to have low activity against the conditionally active polypeptide in blood or human serum around pH 7.2-7.4 to allow delivery of the therapeutic treatment via the bloodstream while minimizing or preventing the conditionally active polypeptide from activation. Thus, for such treatments, it would be advantageous to select a small molecule or ion with a pKa of pH 7.2-7.4 or less to ensure a sufficient amount of ionization of the small molecule at bloodstream pH to significantly affect the activity of the conditionally active polypeptide. At the same time, the pKa of the small molecule or ion must be at or above the pH at which activity of the conditionally active polypeptide is desired to ensure activation of the conditionally active polypeptide by protonation of the small molecule or ion to the free binding site on the conditionally active polypeptide.

[0256] Small molecules or ions preferably have a low molecular weight and / or a relatively small conformation to ensure maximum access to small pockets on the target polypeptide or conditionally active polypeptide by minimizing steric hindrance. Thus, small molecules or ions typically have a molecular weight of less than 900 a.mu, or more preferably less than 500 a.mu, or more preferably less than 200 a.mu, or even more preferably less than 100 a.mu. For example, hydrogen sulfide, disulfide and bicarbonate all have low molecular weights and compact structures that provide access to pockets on the target polypeptide or conditionally active polypeptide, as shown in Examples 13 and 14 below.

[0257] Small molecules or ions may be present in the assays used to select condition activity or environment at substantially the same concentration, e.g., about 20 μM for bicarbonate. In some embodiments, small molecules or ions may be present at different concentrations in different environments, and therefore it may be desirable to simulate this in the assay. For example, disulfide has a higher concentration in a tumor microenvironment than in human serum. Thus, a first assay may simulate a neutral or slightly basic pH and a lower concentration of disulfide in human serum, while a second assay may simulate a tumor microenvironment with an acidic pH and a higher concentration of disulfide. The acidic pH may be in the range of 6.0-6.8, while the neutral or slightly basic pH may be about 7.4. The lower concentration of disulfide for the first assay simulating human serum may be 10 μM or less, or 5 μM, while the higher concentration of disulfide for the second assay simulating a tumor microenvironment may be 30 μM.

[0258] In some embodiments, the conditionally active polypeptide is pH dependent when two or more different small molecules and / or ions are present, such as, for example, a combination of bicarbonate and histidine.

[0259] In the absence of small molecules or ions, a conditionally active polypeptide may lose pH dependence, and thus, in the absence of small molecules or ions, a conditionally active polypeptide may have similar activity between the abnormal pH at which activity is desired and normal physiological pH.

[0260] In certain embodiments, the abnormal pH at which activity is desired is an acidic pH, and the normal physiological pH is a basic or neutral pH. For example, the abnormal pH can be a pH in the range of about 5.5-7.2, or about 6.0-7.0, or about 6.2-6.8. The normal physiological pH can be a pH in the range of greater than 7.2 to less than 7.6. Conditionally active polypeptides that are more active at acidic pH and less active at basic or neutral pH can target tumor microenvironments where the abnormal pH is about 5.5-7.2, or about 6.2-6.8 acidic.

[0261] In other embodiments, the abnormal pH at which activity is desired is a basic pH, and the normal physiological pH is an acidic or neutral pH. For example, the abnormal pH at which the pH-dependent polypeptide is more active may be a basic pH, for example, 7.6 to 7.9, such as in synovial fluid (see Jebens et al., "On the viscosity and pH of synovial fluid and pH of blood," Journal of Bone and Joint Surgery, vol. 41 B, pp. 388-400, 1959). The normal physiological pH may be a pH of blood above 7.2 to 7.6, at which the conditionally active polypeptide is less active. These conditionally active polypeptides are believed to be suitable for targeting joint diseases and arthritis.

[0262] In other embodiments, the conditionally active polypeptide may be designed to target the brain. There is a pH difference on either side of the blood-brain barrier, with the pH on the brain side being about 0.2 pH units lower than the pH of blood or human serum. Thus, the abnormal pH in the brain at which the conditionally active polypeptide is more active may be about 7.0-7.2 (brain pH), whereas normal physiological pH may be greater than 7.2 and less than 7.6.

[0263] The conditionally active polypeptide may be an enzyme, a cytokine, a receptor, particularly a cellular receptor, a regulatory polypeptide, a soluble polypeptide, an antibody, or a hormone.

[0264] The conditionally active polypeptide may be a fragment of a parent polypeptide. For example, the conditionally active polypeptide may be an antibody fragment, a single chain antibody, an enzyme fragment, a receptor fragment, a cytokine fragment, or a hormone fragment. The antibody fragment may be an Fc fragment of an antibody.

[0265] Fc fragments can be used as parent polypeptides to generate conditionally active Fc fragments. Binding of Fc fragments to complement can be used to effect antibody-dependent cell-mediated cytotoxicity. Abnormal pH can be acidic, such as the pH in the tumor microenvironment, ranging from 5.5 to 7.2 or 6.2 to 6.8, whereas normal physiological pH ranges from above 7.2 to below 7.6. Abnormal pH is different from the pH of lysosomes, which typically have a pH around 4.0. Furthermore, lysosomes are where Fc fragments are targeted for degradation like any other polypeptide. Lysosomes lack complement, and cell-mediated cytotoxicity cannot occur via lysosomes.

[0266] A conditionally active polypeptide may have two functional domains, with at least one, and preferably both, having pH-dependent activity. The two functional domains may be evolved simultaneously and selected in a manner that identifies both functional domains in the same mutant polypeptide. Alternatively, the two functional domains may be evolved and selected independently. In this case, the two functional domains may be fused to form a chimeric polypeptide.

[0267] In one embodiment, the conditionally active polypeptide exhibits increased activity at abnormal pHs where activity is desired compared to the parent polypeptide in the presence of a factor such as a protein, and decreased activity at normal physiological pH compared to the parent polypeptide. The protein may be a protein present in blood, human serum, or in a body microenvironment such as a tumor microenvironment, an inflamed region, synovial fluid, or the brain. One suitable protein may be albumin, particularly a mammalian albumin such as bovine albumin or human albumin.

[0268] In one embodiment, a protein such as albumin is present in the assay solution used to screen and select conditionally active polypeptides. In another embodiment, an assay solution having a protein such as albumin can also be used to test the activity of the selected conditionally active polypeptide under the same or different conditions. J. Engineering Conditionally Active Polypeptides

[0269] The selected conditionally active polypeptides of the invention can be further modified using any of the methods described in WO 2017 / 078839 in the sections entitled "Engineering of conditionally active polypeptides," "Engineering masked conditionally active polypeptides," and "Engineering of conditionally active antibodies." Additionally, the conditionally active polypeptides and modified conditionally active polypeptides of the invention can be inserted into viral particles that are oncolytic viruses, as described in WO 2017 / 078839. K. Production of Conditionally Active Polypeptides

[0270] Selected conditionally active polypeptides and modified conditionally active polypeptides of the invention can be produced for therapeutic, prophylactic, diagnostic and research uses using the methods described in WO 2017 / 078839 in the section entitled "Production of the Conditionally Active polypeptides". G. Pharmaceutical Compositions

[0271] Pharmaceutical compositions comprising a conditionally active polypeptide or a modified conditionally active polypeptide, as well as uses of such pharmaceutical compositions, are described in WO 2017 / 078839. The invention extends to pharmaceutical compositions comprising a conditionally active polypeptide or further modified conditionally active polypeptides which may be used for therapeutic, prophylactic and diagnostic applications. L. Uses of Conditionally Active Polypeptides

[0272] The invention also includes the use of the conditionally active polypeptides for the curative or prophylactic treatment of solid tumors, inflamed joints, or brain diseases or disorders.

[0273] Also included within the scope of the present invention is a method of treating a solid tumor, an inflammatory joint, or a brain disease or disorder by administering a conditionally active polypeptide of the present invention to a patient in need of said treatment.

[0274] It should be noted that as used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural references unless the context clearly dictates otherwise. Additionally, the terms "a" (or "an"), "one or more," and "at least one" may be used synonymously herein. The terms "comprising," "including," "having," and "constructed from" may also be used synonymously.

[0275] Unless otherwise indicated, all numerical values ​​expressing quantities of ingredients, properties, such as molecular weights, percentages, ratios, reaction conditions, and the like, used in the specification and claims should be understood to be modified in all instances by the term "about," whether or not the term "about" is present. Thus, unless indicated to the contrary, the numerical parameters set forth in the specification and claims are approximations and may vary depending on the desired properties sought to be achieved by the present disclosure. At the very least, and without attempting to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should be construed at least in light of the number of reported significant digits and by applying ordinary rounding techniques. Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the present disclosure are approximations, the numerical values ​​set forth in the specific examples are reported as precisely as possible. Any numerical value, however, inherently contains certain errors necessarily resulting from the standard deviation found in their respective testing measurements.

[0276] It should be understood that each component, compound, substituent, or parameter disclosed herein is to be construed as disclosed for use alone or in combination with one or more of the other components, compounds, substituents, or parameters disclosed herein.

[0277] It should also be understood that each amount / value or amount / value range of each component, compound, substituent or parameter disclosed herein should also be construed as disclosed in combination with each amount / value or amount / value range disclosed for any other component(s), compound(s), substituent(s) or parameter(s) disclosed herein, and thus any combination of amounts / values ​​or amount / value ranges of two or more components, compounds, substituents or parameters disclosed herein are also disclosed in combination with each other for purposes of this description.

[0278] It is further understood that each range disclosed herein should be interpreted as a disclosure of each specific value within the disclosed range with the same number of significant digits. Thus, a range of 1 to 4 should be interpreted as an explicit disclosure of values ​​1, 2, 3, and 4. It is further understood that each lower limit of each range disclosed herein should be interpreted as a disclosure in combination with each upper limit of each range and each specific value within each range disclosed herein for the same component, compound, substituent, or parameter. Thus, this disclosure should be interpreted as a disclosure of all ranges obtained by combining each lower limit of each range with each upper limit of each range or each specific value within each range, or by combining each upper limit of each range with each specific value within each range.

[0279] Furthermore, a specific amount / value of a component, compound, substituent, or parameter disclosed in the description or examples should be construed as a disclosure of either a lower or upper range limit and thus can be combined with any other lower or upper range limit or specific amount / value of the same component, compound, substituent, or parameter disclosed elsewhere in this application to form a range of the component, compound, substituent, or parameter.

[0280] All documents mentioned in this specification are hereby incorporated by reference in their entirety or in lieu of providing the disclosure in which they were specifically relied upon. Applicants do not intend to offer any disclosed embodiments to the public, and to the extent that any disclosed variations or alternatives may not literally fall within the scope of the claims, they are considered part of this specification under the doctrine of equivalents.

[0281] However, although the foregoing description sets forth numerical features and advantages of the present invention together with details of the structure and function of the present invention, it is to be understood that the disclosure is merely illustrative and that modifications may be made in details, particularly in terms of shape, size and arrangement of elements, within the scope of the principles of the present invention to the fullest extent indicated by the broad general meaning of the terms expressing the scope of the appended claims.

Claims

1. 1. A method for producing a conditionally active antibody or antibody fragment from a parent antibody or antibody fragment, comprising: (i) evolving a parent antibody or antibody fragment by introducing one or more mutations into the parent antibody or antibody fragment to produce one or more variant antibodies or antibody fragments that have a lower pI than the pI of the parent antibody or antibody fragment; (ii) determining which variant antibodies or antibody fragments have a pI lower than that of the parent antibody or antibody fragment and discarding variant antibodies or antibody fragments having a pI equal to or higher than that of the parent antibody or antibody fragment, while retaining variant antibodies or antibody fragments having a pI lower than that of the parent antibody or antibody fragment; (iii) determining an activity of the one or more retained variant antibodies or antibody fragments in a first assay at pH 7.2 to 7.6 and measuring the same activity of the one or more retained variant antibodies or antibody fragments in a second assay at pH 6 to 7; and (iv) selecting a conditionally active antibody or antibody fragment from one or more mutant antibodies or antibody fragments that (a) exhibit activity in the second assay that is at least 1.3, or at least 1.5, or at least 1.7, or at least 2.0, or at least 3.0, or at least 4.0, or at least 6.0, or at least 8.0, or at least 10.0 units higher than the activity exhibited in the first assay, and (b) have a pI that is at least 0.1, or at least 0.2, or at least 0.3, or at least 0.4, or at least 0.5, or at least 0.6, or at least 0.8, or at least 1.0 units lower than the pI of the parent antibody or antibody fragment. The method includes:

2. 2. The method of claim 1, wherein the conditionally active antibody or antibody fragment has a pI below 7.4, or a pI below 7.3, or a pI below 7.2, or a pI below 7.1, or a pI below 7.

0.

3. 3. The method of claim 1 or 2, wherein the one or more mutations comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions of amino acid residues for amino acid residues in the parent antibody or antibody fragment that have a higher pI than the pI of the amino acid substituted in the parent antibody or antibody fragment.

4. 4. The method of any one of claims 1 to 3, wherein the one or more mutations comprise an insertion of 1, 2, 3, 4, or 5 amino acid residues having a lower pI than the pI of the parent antibody or antibody fragment, or an insertion of 1, 2, 3, 4, or 5 amino acid residues having a pI that is at least 0.1, or at least 0.2, or at least 0.3, or at least 0.4, or at least 0.5, or at least 0.6, or at least 0.8, or at least 1.0, or at least 1.2, or at least 1.4, or at least 1.5, or at least 1.7, or at least 2.0 units lower than the pI of the parent antibody or antibody fragment.

5. The method of any one of claims 1 to 4, wherein the one or more mutations comprise deletion of 1, 2, 3, 4 or 5 amino acid residues that have a higher pI than the pI of the parent antibody or antibody fragment.

6. The method of any one of claims 1 to 5, wherein the one or more mutations are located at positions exposed on the surface of the mutant antibody or antibody fragment.

7. Both the first and second assays are carried out in the presence of one or more molecules or ions having a molecular weight of less than 900 a.m.u., or less than 500 a.m.u., or less than 200 a.m.u., or less than 100 a.m.u.; the one or more molecules or ions are selected from histidine, histamine, hydrogenated adenosine diphosphate, hydrogenated adenosine triphosphate, citrate, bicarbonate, acetate, lactate, disulfide, hydrogen sulfide, ammonium, dihydrogen phosphate, and any combination thereof; or the one or more molecules or ions are bicarbonate ions having a concentration in the range of 3 mM to 200 mM, or 5 mM to 150 mM, or 5 mM to 100 mM, or 10 mM to 100 mM, or 20 mM to 100 mM, or 25 mM to 100 mM, or 30 mM to 100 mM, or 35 mM to 100 mM, or 40 mM to 100 mM, or 50 mM to 100 mM; the one or more molecules or ions are disulfide ions having a concentration in the range of 1 mM to 100 mM, or 2 nM to 500 nM, or 3 nM to 200 nM, or 5 nM to 100 nM; or The one or more molecules or ions are selected from sodium bicarbonate, potassium bicarbonate, sodium disulfide, or potassium disulfide; The method according to any one of claims 1 to 6.